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The protective role of high density 
lipoprotein (HDL) against coronary 
heart disease and atherosclerosis 
is well established. Endothelial 
lipase (EL) is a major regulator of 
HDL metabolism and therefore an 
intriguing therapeutic target for 
increasing HDL cholesterol. In this 
thesis, potential factors modulating 
EL expression via transcriptional 
regulation were investigated. Also, 
the effects of VEGF-A in lipid 
metabolism were assessed since its 
role in atherosclerosis is still under 
debate. 
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ABSTRACT 
 
Atherosclerosis is a progressive disease characterized by the accumulation of lipids in the 
arteries. Vascular lipases are a group of enzymes that regulate lipid metabolism by 
hydrolizing triglycerides and phospholipids carried by lipoproteins and as such they play a 
central role in normal vascular function. Endothelial lipase (EL) is a major regulator of high 
density lipoprotein (HDL) metabolism and in inflammatory states, like atherosclerosis, EL 
expression is increased contributing to low HDL cholesterol. This makes EL an intriguing 
therapeutic target for regulating HDL levels. However, its regulation is poorly understood 
and to date has mainly been attributed to inflammatory stimuli.  
The aim of this thesis was to gain more information about the transcriptional regulation 
of EL, and to investigate whether EL expression could be modulated by sulforaphane 
(SFN), a naturally occurring isothiocyanate, and vascular endothelial growth factor-A 
(VEGF-A). Since the role of VEGF-A in atherogenesis has remained controversial, also the 
effects of adenoviral VEGF-A gene transfer on atherosclerosis and lipid metabolism was 
investigated in four different hyperlipidemic mouse models aiming to find out potential 
factors explaining the contradictory findings reported in the literature. 
  In this thesis, EL expression was shown to be regulated by the classical NF-B pathway 
under inflammatory conditions, and this activation was attenuated by SFN. In addition, 
sterol regulatory binding proteins (SREBPs) were demonstrated to be novel regulators of 
EL as these modulated EL expression. VEGF-A was able to inhibit EL and also lipoprotein 
lipase (LPL) expression both in vitro and in vivo leading to changes in plasma lipids. 
However, VEGF-A increased atherosclerosis only in ApoE-/- background indicating some 
mouse model-specific effects. 
In conclusion, SFN reduces EL expression via inhibition of NF-B suggesting that SFN 
could have beneficial effects on lipid metabolism. EL expression is also modulated by 
SREBPs providing one likely mechanism for cells to respond to changes in systemic 
cholesterol levels. Moreover, VEGF-A clearly plays a role in lipid metabolism via regulation 
of EL and LPL. EL and VEGF-A are potential new targets for the treatment of 
atherosclerotic vascular diseases. 
 
 
National Library of Medical Classification: QS 532.5.E7, QU 475, QU 560, WG 550 
Medical Subject Headings: Endothelial Cells; Lipase; Gene Expression Regulation,; Vascular Endothelial 
Growth Factor A; Atherosclerosis; Lipid Metabolism; Lipoprotein Lipase; Genetic Therapy; Models, Animal; 
NF-kappa B  
VI 
 
 
  
VII 
 
 
Kivelä, Annukka 
Endoteelilipaasin transkriptionaalinen säätely ja VEGF-A:n rooli rasva-aineenvaihdunnassa  
Itä-Suomen yliopisto, terveystieteiden tiedekunta 
Publications of the University of Eastern Finland. Dissertations in Health Sciences 226. 2014. 76 s. 
 
ISBN (print): 978-952-61-1421-7 
ISBN (pdf): 978-952-61-1422-4 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706 
 
TIIVISTELMÄ 
 
Ateroskleroosi eli valtimonkovettumatauti on etenevä sairaus, jolle on tyypillistä rasvojen 
kertyminen valtimoiden seinämiin. Verisuonistossa esiintyy ryhmä lipaaseja eli 
vesiliukoisia entsyymejä, jotka osallistuvat rasva-aineenvaihdunnan säätelyyn 
hydrolysoimalla lipoproteiinien osana olevia triglyseridejä ja fosfolipidejä. Endoteelilipaasi 
(endothelial lipase, EL) on tärkeä HDL-kolesterolin säätelijä, jonka ilmentyminen lisääntyy 
tulehduksellisissa sairauksissa, kuten ateroskleroosissa, johtaen madaltuneisiin HDL-
kolesterolitasoihin. Tämän vuoksi EL on kiehtova terapeuttinen kohde HDL-
kolesterolitasojen säätelyssä. EL:n säätely on kuitenkin melko huonosti tunnettu ja sitä on 
tutkittu lähinnä tulehduksen yhteydessä. 
Tämän väitöskirjatutkimuksen tarkoituksena oli saada lisää tietoa EL:n 
transkriptionaalisesta säätelystä sekä selvittää, voiko EL:n ilmentymistä säädellä 
luonnollisesti esiintyvän isotiosyanaatin, sulforafaanin (sulforaphane, SFN), ja verisuonen 
endoteelikasvutekijä A:n (vascular endothelial growth factor A, VEGF-A) vaikutuksesta. 
Koska VEGF-A:n rooli ateroskleroosin kehittymisessä on edelleen kiistanalainen, 
adenovirusvälitteisen VEGF-A-geeninsiirron vaikutuksia ateroskleroosiin ja rasva-
aineenvaihduntaan tutkittiin neljässä eri hyperlipidemisessä hiirimallissa tarkoituksena 
selvittää mahdollisia tekijöitä, jotka selventäisivät aiempia ristiriitaisia havaintoja. 
Tutkimuksessa havaittiin, että klassinen NF-B-signalointireitti säätelee EL:n 
ilmentymistä vasteena tulehdukselle, ja SFN vähensi tätä NF-B-välitteistä EL:n 
ilmentymistä. Lisäksi uutena löydöksenä havaittiin, että sterolisäätöiseen elementtiin 
sitoutuvat proteiinit (sterol regulatory element binding proteins, SREBPs) voivat säädellä 
EL:n ilmentymistä. VEGF-A hiljensi EL:n ja lipoproteiinilipaasin (lipoprotein lipase, LPL) 
ilmentymistä, mikä johti muutoksiin plasman rasvatasoissa. VEGF-A kuitenkin lisäsi 
ateroskleroosia ainoastaan ApoE-/--taustaisissa hiirimalleissa viitaten siihen, että VEGF-A:n 
vaikutukset olivat hiirimallikohtaisia. 
Yhteenvetona voidaan todeta, että SFN vähentää EL:n ilmentymistä hiljentämällä NF-B-
signalointireittiä viitaten siihen, että SFN:lla voi olla hyödyllisiä vaikutuksia rasva-
aineenvaihdunnassa. Myös SREBP-säätelytekijät säätelevät EL:n ilmentymistä, mikä on 
yksi mahdollinen mekanismi, jolla solut vastaavat muutoksiin verisuonen 
kolesterolitasoissa. Lisäksi VEGF-A:lla on selkeästi osuus rasva-aineenvaihdunnassa EL:n ja 
LPL:n säätelyn kautta. EL ja VEGF-A ovat uusia mahdollisia terapeuttisia kohteita 
ateroskleroottisten verisuonisairauksien hoidossa. 
 
Luokitus: QS 532.5.E7, QU 475, QU 560, WG 550 
Yleinen Suomalainen asiasanasto: endoteelilipaasi, lipaasit, ateroskleroosi, aineenvaihdunta, rasvat, geenit, 
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 1 Introduction 
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality in the 
world. Atherosclerosis, one of the key underlying features behind CVD, is a progressive 
inflammatory disease, where accumulation of lipids and fibrous material contribute to the 
formation of atherosclerotic lesions in the arteries hindering the blood flow by often 
narrowing the lumen. (Perk et al. 2012, Lusis 2000). 
Lipid metabolism plays a central role in normal vascular function. Serum cholesterol is 
carried by lipoprotein particles, primarily in low density lipoproteins (LDLs) that transport 
lipids to peripheral tissues. In atherosclerosis the levels of serum cholesterol are usually 
increased, which leads to the key initiating process in atherogenesis, the accumulation of 
lipoproteins within the subendothelial extracellular matrix of the vessel wall. High density 
lipoprotein (HDL) promotes efflux of cholesterol from cells and transports it to the liver. 
Therefore, high levels of HDL are desired for protecting vasculature from lipid stress. 
(Glass, Witztum 2001). Vascular lipases are a group of enzymes that regulate dietary fat 
absorption, energy homeostasis and circulating lipoprotein levels by metabolizing 
triglycerides and phospholipids carried by lipoproteins. Endothelial lipase (EL), the newest 
member of vascular lipases, has an important role in the regulation of HDL metabolism 
(Ishida et al. 2003), which makes it an intriguing therapeutic target for regulating HDL 
levels. 
The vascular endothelial growth factor-A (VEGF-A) is a key angiogenic factor in 
vascular development in physiological and pathological processes. The use of VEGF-A for 
therapeutic angiogenesis has raised questions due to concerns that VEGF-A could also 
enhance pathological neovascularization linked to the growth and progression of 
atherosclerotic lesions (Ylä-Herttuala et al. 2007). Debate concerning the role of VEGF-A in 
atherogenesis is still ongoing partly because of inconsistent results from different animal 
models.  
The aim of this thesis was to investigate factors regulating the expression of EL. Since 
there is some evidence that VEGF-A could be involved in lipid metabolism, also the effects 
of VEGF-A on lipid metabolism, especially on EL, were studied. Furthermore, the effects of 
VEGF-A on atherosclerosis were investigated in order to identify potential factors 
explaining the contradictory findings obtained from different animal studies. 
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2  Review of the literature 
2.1 CARDIOVASCULAR DISEASES 
CVDs are the major cause of death in the world and in Europe alone over 4 million people 
die from CVDs every year. These diseases are also an important cause of disability and 
contribute substantially to the economic costs of the health care system. There are various 
clinical manifestations of CVDs including coronary heart disease, hypertensive heart 
disease, heart failure, peripheral arterial disease and stroke. The underlying feature of most 
of the CVDs is atherosclerosis and since this developes over many decades and is usually 
advanced by the time the symptoms appear, death from CVD may occur suddenly and 
before medical care is available. (Perk et al. 2012). 
Development of CVD strongly relates to lifestyle and modifiable physiological and 
biochemical factors. The most common risk factors for CVD are considered to be high blood 
cholesterol, hypertension, smoking, obesity, unhealthy diet, physical inactivity and 
diabetes. In addition, various genetic factors associated with an increased risk for CVD 
have been identified. (Perk et al. 2012). Current treatments of CVD consist of lifestyle 
changes, lipid-lowering and antithrombotic drugs, such as statins and aspirin, in addition 
to drugs used for treatment of blood pressure and diabetes, and invasive operations 
including coronary angioplasty, stenting, coronary artery bypass grafting and peripheral 
bypass surgeries (Perk et al. 2012, Fajadet, Chieffo 2012). 
2.1.1 Atherosclerosis 
Atherosclerosis is a progressive disease characterized by the accumulation of lipids, 
calcification and fibrous material in the large arteries. Arteries consist of three 
morphologically different layers: intima, media and adventitia. Intima, the innermost layer, 
consists of a monolayer of endothelial cells lining the luminal surface and the elastic lamina 
lining the peripheral side (Figure 1). Normally the intima is very thin containing mainly 
proteoglycans and collagen. Media, the middle layer, is mainly formed by smooth muscle 
cells (SMCs; Figure 1). Adventitia, the outer layer, consists of connective tissue. (Lusis 
2000). Atherosclerotic lesion formation is primarily distributed to the sites of vasculature 
with so-called lesion-prone areas such as branches, bifurcations and curvatures. In these 
lesion-prone areas, there is adaptive intimal thickening due to an attempt by the tissue to 
maintain normal conditions in response to mechanical stresses such as turbulent blood flow 
and low shear stress .(Stary et al. 1992). Progression of atherosclerosis can be classified into 
following six different lesion types (I-VI): initial lesion (I), fatty streak (II), intermediate 
lesion (III), atheroma (IV), fibroatheroma (V) and complicated lesion (VI; Figure 1; Stary et 
al. 1994, Stary et al. 1995). 
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Figure 1. Different lesion types in the development of atherosclerosis. ECs, endothelial cells; 
SMCs, smooth muscle cells. Modified from Stary et al (2008) and Lusis (2000). 
 
Formation of early atherosclerotic lesions (I-II) begins when LDL starts to accumulate in 
the intima, where it is further modified (Ylä-Herttuala et al. 1989). This modified LDL, for 
example oxidized LDL, stimulates endothelial cells to produce proinflammatory cytokines 
attracting leukocytes and monocytes into the intima. Monocytes differentiate into 
macrophages that engulf modified LDL leading to formation of foam cells. (Lusis 2000, 
Glass, Witztum 2001). Further accumulation of lipids turns foam cells into fatty streaks, 
which are characteristic features of type II lesions. After this, the number of intimal SMCs, 
mainly derived from the media, starts to increase and they also contain lipid droplets. Type 
III lesion is the morphological and chemical intermediate between type II and advanced 
lesions, and is characterized by pools of extracellular lipid. Lesion types I-III are clinically 
silent and do not lead directly to complications. They all are relatively small lesions 
containing abnormal accumulation of lipoproteins and cholesteryl esters. In the intima, 
there is an increased number of cells, mostly macrophages, and accumulation of lipids can 
be seen as lipid droplets. (Stary et al. 1994). In addition, the intima also contains T-cells and 
mast cells; inflammatory cells that are involved in the initation and progression of 
atherosclerotic lesions (Kovanen 2007). Nevertheless, changes in the intimal architecture are 
still minimal or even absent, and the media as well as adventitia are unaffected (Stary et al. 
1994). 
When the amount of extracellular lipid increases, it forms a well-defined region known 
as the lipid core in the intima. The lipid core is a characteristic feature of type IV lesion, 
called atheroma, which is the first lesion type considered advanced since the formation of 
the lipid core leads to severe intimal disorganization. However, atheroma usually does not 
narrow the vascular lumen. (Stary et al. 1995). In response to inflammatory cytokines and 
growth factors, intimal SMCs start to accumulate and secrete extracellular matrix proteins, 
which lead to formation of a fibrous cap structure above the lipid core. This defines type V 
lesions which are otherwise known as fibroatheroma. (Lusis 2000). The inflammatory 
environment of the intima further induces the death of lipid-loaded macrophages and 
SMCs, and the formation of a necrotic core typical for more advanced lesions. Also, 
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calcification and neovascularization may occur making the plaque more unstable. (Glass, 
Witztum 2001). With type V lesions, arteries are narrowed, generally more than with type 
IV lesions. Narrowing of the lumen by the growing lesion may cause ischemic symptoms, 
however, clinically more serious events such as myocardial infarction or stroke result from 
complicated type VI lesions. Type VI lesions are characterized by one or more of the 
following features: lesion surface rupture, hematoma or hemorrhage and thrombosis. (Stary 
et al. 1995). More recent classification of lesions also contains complicated lesion types VII 
and VIII. This classification is only reflecting the directions in which lesion types may 
change morphologically; in type VII lesion calcification predominates while in type VIII 
fibrous tissue changes predominate (Stary 2000). 
 
2.1.1.1 Cholesterol accumulation in the vessel wall 
The key initiating process in atherogenesis is the subendothelial accumulation of 
lipoproteins. In this process the endothelium lining the blood vessels plays a crucial role. In 
the vasculature, intact endothelium is needed for the regulation of blood clotting, 
inflammation, vascular tone and contraction. Due to the location, between the blood and 
tissues, endothelial cells also need to adapt continuously to respond to changes occurring in 
the plasma, interstinal fluid or the surroundings. To maintain vascular homeostasis at the 
luminal surface, endothelial cells possess several characteristic features. They are coated by 
a glycocalyx, charged in part because of the distribution of anionic proteins and 
proteoglycans. Endothelial cells also express several plasma membrane receptors and 
contain extensive cytoskeleton as well as different organelles, vesicles and interendothelial 
cell junctions for trafficking of plasma fluids and proteins. (Sima, Stancu & Simionescu 
2009). 
There are two different pathways for endothelial cells to sort and gate plasma molecules; 
endocytotic and transcytotic pathways. By endocytosis, which can be either non-specific or 
specific and receptor-mediated, lipoproteins are directed to the lysosomal compartments, 
where they are degraded to provide amino acids, cholesterol, phospholipids or fatty acids. 
Interestingly, endothelial cells never accumulate lipids like macrophages or SMCs and 
therefore, if lipoproteins are not degraded via endocytosis, endothelial cells pass them 
through via transcytosis. Transcytosis can also be either a non-specific or specific process, 
and it is further divided to transcellular (via caveolae) and paracellular pathways (through 
endothelial junctions). The transcellular pathway with cargo-vesicles and their channels is 
the main pathway for macromolecules, such as lipoproteins, whereas the paracellular 
pathway is used for transport of water and ions. (Simionescu 2007). 
Many different mechanisms and models have been proposed to explain cholesterol 
accumulation in the vessel wall (Kruth 2001, Williams, Tabas 1995). Probably the most 
widely supported model explaining cholesterol accumulation is the Response-to-Retention 
model. This model emphasizes retention of apolipoprotein (apo) B-containing lipoproteins 
within the vessel wall as the determining factor in cholesterol accumulation (Williams, 
Tabas 1995, Ylä-Herttuala et al. 1988). This model concentrates on three main points leading 
to retention and overall accumulation of intimal cholesterol. Firstly, lipoprotein entry and 
retention is dependent on sustained plasma levels of apoB lipoproteins. If there is 
insufficient amount of apoB lipoproteins, the probability that they will enter and be 
retained in the subendothelial space decreases. Secondly, lipoprotein retention in the intima 
is mediated by the physical interaction between lipoproteins and subendothelial matrix 
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molecules, primarily the proteoglycans. (Boren et al. 2000, Ylä-Herttuala et al. 1986, Camejo 
1982, Tabas, Williams & Boren 2007). Thirdly, there are accessory molecules within the 
arterial wall such as mast cell-produced proteases, lipoprotein lipase (LPL), secretory 
sphingomyelinase and secretory phospholipase A2 that promote lipoprotein retention 
(Kovanen 2007). As a consequence of retention, lipoproteins, especially LDL, undergo 
several modifications such as oxidation and aggregation and start to accumulate (Witztum, 
Steinberg 1991, Öörni et al. 2000). Modified LDL further triggers an inflammatory response 
at the site of lipoprotein retention and is finally taken up by macrophages (Pentikäinen et 
al. 2000). 
 
2.1.1.2 Inflammation in atherosclerosis 
In addition to cholesterol accumulation, inflammation plays an important role in the 
initiation and progression of atherosclerosis. A triggering event for inflammatory processes 
to take place in the vessel wall is the accumulation of lipoproteins, which changes 
endothelial cells both structurally and functionally. Endothelial cells switch to a secretory 
phenotype with many copies of the rough endoplasmic reticulum, Golgi apparatus and 
calveolae, and these cells start to produce a number of pro-inflammatory molecules. 
(Simionescu 2007).  First, endothelial cells start to express various adhesion molecules, 
vascular cell adhesion molecule 1 (VCAM-1) being probably the most important one. 
Adhesion molecules bind monocytes to the endothelium and after these cells have adhered 
firmly, they migrate through the endothelium. In the intima monocytes differentiate into 
macrophages. Then monocyte chemoattractant protein 1 (MCP-1), produced by endothelial 
cells, macrophages and SMCs, attracts more inflammatory cells into the intima. When 
macrophages take up the modified LDL, they form foam cells, which are hallmarks of the 
arterial lesion. Macrophage colony-stimulating factor (M-CSF) is a cytokine that stimulates 
several steps of transition of the monocyte to the lipid-laden macrophage. Macrophage 
foam cells further produce various inflammatory cytokines hence maintaining the 
inflammation at the site of injury. As a consequence of lipid accumulation and the 
subsequent inflammatory process, endothelial dysfunction develops. Many of the genes 
that are involved in the inflammatory events in the vessel wall are under direct 
transcriptional regulation by the nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-B).  (Libby 2002). 
 
2.1.1.2.1 NF-B 
NF-B is a transcription factor mediating the transcription of multiple genes involved in 
inflammation, immunity, cell survival and cell proliferation. The NF-B family of proteins 
contains five members: p65, p50, p52, c-Rel and RelB. In its inactive state, NF-B is retained 
in the cytoplasm as a homo- or heterodimer (in the classical pathway usually p65-p50) due 
to the association of inhibitory proteins IB, IB and IB. Upon inflammatory stimuli, 
IB-kinase (IKK) complex containing IKK1, IKK2 and a regulatory subunit NF-B essential 
modulator (NEMO) is activated leading to phosphorylation of the inhibitory IB proteins. 
Subsequent polyubiquitination and proteosomal degradation of IB releases NF-B to be 
translocated to the nucleus where it binds to DNA and regulates transcription of its target 
genes. The consensus sequence for NF-B binding is 5´-GGGRNWYYCC-3´. Transcription 
of target genes is further regulated via post-translational modifications of NF-B that affect 
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the ability of NF-B to interact with transcriptional co-factors. The classical pathway for 
NF-B activation is presented in Figure 2. (Hayden, Ghosh 2008). 
 
 
 
Figure 2. The classical pathway for NF-B activation. Upon inflammatory stimulus, IKK complex 
is activated further phosphorylating IB protein, which leads to degradation of IB and liberation 
of NF-B complex. Liberated NF-B complex localizes to the nucleus, where it binds to its target 
sequence and mediates transcription of its target genes. Modified from Hayden and Ghosh 
(2008). 
 
Proinflammatory pathways regulated by NF-B also contribute to the development of 
atherosclerosis. NF-B controls directly the expression of several genes involved in the 
initiation and progression of atherosclerosis, including tumor necrosis factor- (TNF-), 
MCP-1, M-CSF, VCAM-1 and intracellular adhesion molecule (ICAM)-1. In addition, 
activated NF-B has been detected in SMCs, macrophages and endothelial cells in human 
atherosclerotic lesions but not in healthy vessels. (Brand et al. 1996). Furthermore, the role 
of NF-B in atherogenesis has been studied in different hyperlipidemic mouse models. 
Endothelial cell-specific knockout of NEMO in apoE-deficient (ApoE-/-) mice decreased the 
expression of adhesion molecules and pro-inflammatory mediators with subsequent 
reduction in both the size and severity of atherosclerotic lesions (Gareus et al. 2008). Also, 
the transplantation of bone marrow from mice with hematopoietic cells deficient in NF-
B1-gene (p50) into a low density lipoprotein receptor-deficient (LDLR-/-) mouse resulted in 
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a reduced number and size of atherosclerotic lesions. Surprisingly, lesions also exhibited an 
almost complete loss of foam cells and their phenotype was highly inflammatory. (Kanters 
et al. 2004). Finally, A20, a negative regulator of NF-B, was anti-atherogenic in ApoE-/- 
mice as it decreased the lesion size (Wolfrum et al. 2007). 
 
2.1.1.2.2 Sulforaphane as an anti-inflammatory agent 
Sulforaphane (1-isothiocyanato-4-methylsulfinylbutane, SFN) is a naturally occurring 
aliphatic isothiocyanate. It is found abundantly in a glucosinolate precursor form in 
cruciferous vegetables such as broccoli. SFN is a well known modulator of multiple cellular 
targets involved in cancer prevention (Cheung, Kong 2010). In addition, SFN has been 
under active research also as an anti-inflammatory agent.  
NF-B is one of the main molecular targets for SFN-mediated anti-inflammatory effects. 
Heiss et al. reported that SFN downregulated lipopolysaccharide-induced inducible nitric-
oxide synthase, cyclooxygenase-2 and TNF- expression in macrophages due to inhibition 
on NF-B DNA binding. In addition, SFN retarded de novo synthesis of IB, but had no 
effect on nuclear localization of p65 or p50. (Heiss et al. 2001).  SFN has also been shown to 
inhibit monocyte adhesion by reducing adhesion molecules (VCAM-1, ICAM-1) expression 
in SMCs and endothelial cells via suppression of NF-B. Both NF-B nuclear translocation 
and IB degradation were inhibited by SFN. (Kim et al. 2012, Liu et al. 2008).  In addition 
to NF-B, nuclear factor-E2-related factor 2 (Nrf2) has been reported to mediate anti-
inflammatory effects of SFN (Lin et al. 2008).  
2.2 LIPOPROTEIN METABOLISM 
Cholesterol is an important component of cell membranes and a precursor for the 
biosynthesis of steroid hormones, bile acids and vitamin D. Circulating cholesterol 
originates either from the diet or it is synthesized endogenously by all animal cells in a 
process catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. 
(Brown, Dana & Goldstein 1973). Both endogenously synthesized cholesterol and 
cholesterol derived from the diet are transported predominantly as cholesteryl esters 
associated with circulating lipoprotein particles. The handling of lipoproteins in the body, 
that is lipoprotein metabolism, is divided into two pathways, exogenous and endogenous, 
depending on whether the lipoproteins in question are composed of dietary lipids or 
whether they originate from the liver. Efflux of excess cholesterol from the peripheral 
tissues occurs via reverse cholesterol transport, a pathway required to maintain cellular 
cholesterol homeostasis. (Grundy 1978, Hegele 2009). 
2.2.1 Lipoproteins 
The insolubility of cholesterol and triglycerides in plasma requires that they are transported 
in spherical macromolecular structures called lipoproteins. Lipoprotein particles have a 
central core of neutral lipids, primarily triglycerides and cholesteryl esters, surrounded by a 
coat of phospholipids, free cholesterol and non-covalently bound apolipoproteins. (Hegele 
2009). Lipoproteins are classified by the type and ratio of proteins and lipids into following 
five major lipoprotein classes: chylomicrons, very low density lipoproteins (VLDL), 
intermediate density lipoproteins (IDL), LDLs and HDLs (Table 1; Mahley et al. 1984). 
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Chylomicrons are the largest lipoprotein particles, made up primarily of triglycerides. 
They are produced by enterocytes of the small intestine as nascent chylomicrons that 
contain apoB-48 as a major protein. While circulating in blood, chylomicrons exchange 
apolipoproteins, mainly apoCs and apoE, with HDLs and become mature chylomicrons. 
Chylomicrons transport dietary lipids to peripheral tissues, where their triglycerides are 
unloaded by LPL. As a consequence, chylomicron remnants are formed and can be taken 
up by the liver. (Nakajima et al. 2011). 
VLDL particles are triglyceride-rich particles secreted continuously from the liver. Their 
main function is to deliver triglycerides to the periphery and they contain apoB-100 as a 
major protein. VLDLs also exchange apolipoproteins with HDLs to become mature VLDL 
particles that can be lipolyzed to VLDL remnants by LPL. The final VLDL remnant 
composition is modulated by the cholesterol ester transfer protein (CETP) that exchanges 
cholesteryl esters and triglycerides between VLDLs and HDLs. (Nakajima et al. 2011). 
As more and more triglycerides are removed from the VLDL by LPL and CETP, the 
composition of the molecule changes and it becomes IDL that has a core containing roughly 
50% triglycerides and 50% cholesteryl esters. IDL particles are either taken up by the liver 
or further converted to LDL by the actions of hepatic lipase (HL), LPL and CETP. Like in 
VLDL and IDL particles, apoB-100 is the major protein in LDL. The core of a LDL particle is 
rich in cholesteryl esters and accounts for the majority of cholesterol in the circulation. 
(Goldstein, Brown 1977, Dominiczak, Caslake 2011). 
HDLs are the smallest particles of lipoproteins. There are three different subclasses of 
HDL particles: nascent (pre-beta) HDL, HDL3 and HDL2. Nascent HDL is a phospholipid-
rich discoidal particle that carries apoA-I as a major protein. When nascent HDL collects 
cholesterol from peripheral cells, it is esterified by lecithin-cholesterol acyltransferase 
(LCAT) leading to an increase in the HDL particle size to spherical HDL3 particle that has a 
core rich in cholesteryl esters. The HDL3 composition is further modulated by CETP that 
exchanges HDL cholesteryl esters for triglycerides and apolipoproteins within triglyceride-
rich lipoproteins. This process enlarges HDL3 particles to HDL2 particles that subsequently 
unload cholesteryl esters into the liver. (Dominiczak, Caslake 2011). 
 
Table 1. Summary of the lipoprotein classes. Adapted from Hegele (2009), Dominiczak & 
Caslake (2011) and Hevonoja et al (2000). 
Lipoprotein 
class 
Diameter 
(nm) 
Density 
(g/ml) 
TG (% by 
weight) 
CE (% by 
weight) 
Protein (% 
by weight) 
Apolipoproteins 
Chylomicron 75-1000 <0.95 80-95 2-4 1-2 A (I,II,IV,V), B-48,  
C (I,II,III), E 
VLDL 80-200 0.95-
1.006 
45-65 16-22 6-10 A (I,II,V), B-100,  
C (I,II,III), E 
IDL 25-40 1.006-
1.019 
24-30 30-35 10-12 B-100, C (I,II,III), E 
LDL 18-21 1.019-
1.063 
4-8 45-50 18-22 B-100 
HDL 9-13 1.063-
1.21 
2-7 15-20 45-55 A (I,II,IV,V),  
C (I,II,III), E 
TG, triglyceride; CE, cholesteryl ester 
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2.2.1.1 Apolipoproteins 
Apolipoproteins are multifunctional components present on the surface of lipoproteins 
(Table 1). They are predominantly synthesized by the liver and intestine, and classified by 
alphabetical designation. Apolipoproteins serve as templates for the assembly of 
lipoprotein particles, they maintain the lipoprotein structure and are responsible for their 
uptake and metabolism via receptor recognition. They also regulate the activities of 
different enzymes involved in lipid metabolism. (Mahley et al. 1984, Dominiczak, Caslake 
2011). 
The apoA class contains proteins A-I, A-IV and A-V, all of which are part of the same 
APOA1/C3/A4/A5 gene cluster located on chromosome 11, and A-II which is located on 
chromosome 1. ApoA-I constitutes 70% of HDL apolipoproteins and its concentration is 
controlled by its degradation rate since lipid-free apoA-I particles are rapidly degraded. It 
activates LCAT and possesses anti-inflammatory and antioxidant properties. (Dominiczak, 
Caslake 2011). ApoA-I also plays a major role in cholesterol efflux from macrophages and 
other cells via adenosine-triphosphate (ATP)-binding cassette transporter A1 (ABCA1) 
(Maiga, Kalopissis & Chabert 2013). ApoA-II is the second most abundant protein in HDL 
accounting for 20% of HDL protein. It participates in ABCA1-mediated HDL formation 
together with apoA-I and it stabilizes HDL in the circulation. ApoA-II also inhibits EL, LPL 
and HL activities. ApoA-IV is incorporated into nascent chylomicrons in the intestine and it 
mainly participates in intestinal lipid absorption and chylomicron assembly. It is also 
present in HDL. Since apoA-IV is relatively hydrophilic, it can be displaced from 
lipoproteins and circulate predominantly as a lipid-free protein. (Dominiczak, Caslake 
2011). ApoA-V plays a role in hepatic VLDL synthesis and secretion and the gene coding 
for apoA-V is strongly associated with plasma triglyceride concentration (Calandra et al. 
2006). It also activates LPL (Dominiczak, Caslake 2011). 
The apoB proteins B-100 and B-48 are produced from a single gene located on 
chromosome 2. They are the only non-exchangeable members of the apolipoprotein family. 
(Hevonoja et al. 2000). ApoB-100 is synthesized in the hepatocytes and it resides in the 
VLDL, IDL and LDL particles at a ratio of one molecule per particle. It also serves as a 
ligand for LDL receptor. ApoB-48 is synthesized and continuously secreted by enterocytes, 
and it is present in chylomicrons and their remnants also at a ratio of one molecule per 
particle. Since apoB-48 does not have a LDL receptor binding domain, chylomicron 
remnants are recognized and taken up via apoE interaction. (Mahley et al. 1984, 
Dominiczak, Caslake 2011). 
The apoC class of proteins consists of C-I and C-II located on chromosome 19, and C-III 
that is a part of APOA1/C3/A4/A5 gene cluster. They all participate in the assembly of 
VLDL and chylomicrons. ApoC-I and III are inhibitors of LPL whereas ApoC-II is a co-
factor and activator of LPL. ApoC-I and III can also inhibit apoE binding to LDL receptor 
related protein (LRP). In addition, ApoC-I activates LCAT and inhibits CETP. (Dominiczak, 
Caslake 2011). 
ApoE is widely present in different lipoprotein classes. It binds to LDL receptor, VLDL 
receptor and LRP and facilitates clearance of chylomicrons and VLDLs. In addition, it 
mediates the binding of lipoproteins to heparan sulfate proteoglycans (HSPGs). (Mahley et 
al. 1984). However, over-expression of apoE leads to hypertriglyceridaemia due to 
stimulation of VLDL production and decrease in its clearance. Thus, optimal expression of 
apoE is crucial for normal metabolism of triglyceride-rich lipoproteins. (Huang 2010). 
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Approximately 60% of plasma apoE is present in HDLs that exchange it with other 
lipoproteins. It is also synthesized by macrophages, where it controls cholesterol efflux 
from cells (Mazzone, Reardon 1994). In addition, apoE activates LPL, HL and LCAT 
(Dominiczak, Caslake 2011). 
2.2.2 Exogenous pathway 
The exogenous pathway of lipid metabolism is the metabolism of dietary lipids. The 
exogenous pathway starts in the intestine where complex lipids of diet are degraded, 
absorbed by enterocytes and assembled into nascent chylomicrons carrying apoB-48 and 
apoAs. First chylomicrons are secreted into the lymph, and then quite rapidly into the 
blood via ductus thoracicus. Once in the general circulation chylomicrons receive apoCs 
and apoE normally from HDL and become mature chylomicrons. (Grundy 1978, 
Dominiczak, Caslake 2011). Chylomicron apoC-II enables LPL to become active and 
recognize chylomicron particles that further undergo hydrolysis of core triglycerides on the 
luminal surface of vascular endothelial cells mainly in the capillaries of adipose tissue, 
skeletal muscles and heart (Nakajima et al. 2011). This hydrolysis, catalyzed by LPL, 
provides non-esterified fatty acids and 2-monoacylglycerol for tissue usage in several ways. 
In addition, fatty acids can be oxidized to provide an energy source in the muscle (Mead, 
Irvine & Ramji 2002). The half-life of chylomicron triglycerides is very short, only 
approximately 5 minutes (Nakajima et al. 2011). In the reaction, catalyzed by LPL, 
chylomicron particles decrease in size, and apoAs and most apoCs are returned to HDL. 
Finally, the smaller chylomicron remnants are able to permeate the fenestrated 
endothelium that separates the hepatocytes surface and the space of Disse from circulation 
(Cooper 1997). In the liver, LDL receptors and LRP, on the surface of the hepatocytes, clear 
chylomicron remnants via an interaction with chylomicron apoE (Mahley et al. 1984). The 
exogenous pathway is illustrated in Figure 3.  
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Figure 3. Exogenous pathway of lipoprotein metabolism. Dietary lipids are degraded in the 
intestine and are assembled into chylomicrons (CM). In the general circulation chylomicron core 
triglycerides undergo hydrolysis by LPL, which creates chylomicron remnants that are taken up 
by the liver via LRP and LDL receptors (LDLR). Modified from Dominiczak and Caslake (2011). 
2.2.3 Endogenous pathway 
The endogenously produced triglycerides and cholesterol are secreted from the liver in 
VLDL particles. These nascent VLDL particles contain apoB-100 as the major protein but 
they also aquire apoAs (A-I, A-II and A-IV), apoCs and apoE from HDL once they are 
secreted into the circulation. Like chylomicron particles, VLDLs undergo apoC-II-mediated 
hydrolysis by LPL, providing fatty acids and 2-monoacylglycerol for tissues. This 
transforms VLDLs to smaller remnants that lose ApoAs back to HDL. VLDL remnants are 
further modified by CETP that exchanges remnant triglycerides for cholesteryl esters of 
HDL. After decreasing in size, VLDL remnant particles become IDLs that can be 
internalized into the liver via apoE-mediated interaction with LDL receptor. Internalization 
of IDLs occurs in parallel to further lipolysis by HL and LPL, and during this process IDLs 
lose apoCs and apoE and become LDLs. (Grundy 1978, Dominiczak, Caslake 2011). ApoB-
100, the main apolipoprotein in LDL, finally controls the uptake of LDLs by LDL receptor 
into the liver (Brown, Goldstein 1986). The endogenous pathway is illustrated in Figure 4.  
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Figure 4. Endogenous pathway of lipoprotein metabolism. Endogenously produced triglycerides 
(TG) are assembled into VLDL particles in the liver. In the circulation, VLDL triglycerides 
undergo hydrolysis by LPL, which creates VLDL remnants. These VLDL remnants are further 
modified by CETP, which produces smaller IDL particles that can be taken up by the liver via 
LDL receptor (LDLR). IDL particles can also undergo further lipolysis by HL and LPL and become 
LDL particles. Finally, LDLs are internalized into the liver via LDLR. Modified from Dominiczak 
and Caslake (2011). CE, cholesteryl ester. 
2.2.4 Reverse cholesterol transport 
Reverse cholesterol transport is a pathway of removal of cholesterol from the periphery to 
the liver and ultimately to fecal excretion. The first phase of reverse cholesterol transport is 
cholesterol efflux from macrophages and other cells to HDL. The smallest forms of HDL, 
nascent HDLs, are formed when lipid-poor apoA-I and apoA-II complexes are lipidated 
with free cholesterol via ABCA1 interaction at the plasma membrane. (Maiga, Kalopissis & 
Chabert 2013). Liver and intestine account for ~70% and ~20% of plasma HDL cholesterol, 
respectively, whereas adipose tissue, which contains a large free cholesterol pool, may 
contribute up to 15%. Although macrophages contribute little to plasma HDL levels, 
ABCA1-mediated cholesterol efflux is a key event to protect macrophages in the vessel wall 
from excessive cholesterol accumulation, ultimately leading to atherosclerosis. Nascent 
HDL can also be assembled on the matrix of the lipid-poor apoE (E-HDL) that facilitates 
both the efflux of cholesterol from cells and its delivery to the liver. Free cholesterol within 
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nascent HDL is esterified by LCAT that cleaves the sn-2 fatty acid of lecithin and transfers it 
to free 3-β-hydroxyl group of cholesterol. Accumulation of cholesteryl esters changes the 
particles to bigger HDL3 particles. HDL3 particles are further enlarged to HDL2 particles 
by the activity of CETP that transfers cholesteryl esters to triglyceride-rich lipoproteins in 
exchange for triglycerides and apolipoproteins. The bigger HDL particles, HDL3 and 2, and 
E-HDL can also collect cholesterol from macrophages via ATP-binding cassette transporter 
G1 (ABCG1) in a process that does not require direct binding of HDL to ABCG1. (Rosenson 
et al. 2012). In addition, cholesterol can be transferred to HDL via passive diffusion or 
scavenger receptor class B type 1 (SR-BI) in processes that are bidirectional (Krieger 1999).  
The next step in reverse cholesterol transport is hepatic cholesterol uptake. SR-BI plays a 
central role in this uptake of HDL cholesterol (Krieger 1999). It does so primarily from large 
cholesterol-enriched HDL particles, via interaction with apoA-I in a process that does not 
require particle internalization. ApoA-I instead, starts to recruit phospholipids and 
cholesterol from cells or is catabolized in the kidneys (Clay, Barter 1996). Finally, 
cholesterol is converted to bile acids and secreted from the liver to feces, which is the last 
step of reverse cholesterol transport (Rosenson et al. 2012). The reverse cholesterol transport 
pathway is illustrated in Figure 5.  
 
Figure 5. Reverse cholesterol transport pathway. When lipid-poor apoA-I complexes are 
lipidated with free cholesterol via ABCA1 interaction in the plasma membrane, nascent HDL 
(nHDL) particles are formed. Free cholesterol within nascent HDLs is esterified by LCAT, which 
leads to accumulation of cholesteryl esters (CE) changing these particles to bigger HDL3 
particles. HDL3 particles are further enlarged to HDL2 particles by the activity of CETP. The 
bigger HDL3 and HDL2 particles can also collect cholesterol from tissues via ABCG1 and SR-BI. 
HDL cholesterol is taken up by the liver via SR-BI. The process does not require particle 
internalization, and therefore the lipid-depleted HDL particles directly re-enter circulation. 
Finally, cholesterol is converted to bile acids and secreted from the liver to feces. Modified from 
Dominiczak and Caslake (2011). 
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Phospholipid transfer protein (PLTP), EL and HL are also able to modulate the 
composition of HDL particles, however, their role in the regulation of reverse cholesterol 
transport is still somewhat unclear. PLTP is a protein that transfers phospholipids from 
apoB-containing lipoproteins to HDL. The association between HDL cholesterol and PLTP 
is inconsistent since both transgenic and gene knockout mice have been reported to have 
reduced HDL cholesterol levels. (van Haperen et al. 2000, Jiang et al. 1999). In addition, 
there is no clear evidence whether PLTP increases or decreases cholesterol efflux from 
macrophages (Vikstedt et al. 2007, Samyn et al. 2009). In the case of EL, there is also 
evidence that it can work both ways, that is it can promote or inhibit macrophage 
cholesterol efflux (Yasuda, Ishida & Rader 2010). However, in the hepatic cholesterol 
uptake, EL is a key regulator as it promotes selective uptake of cholesteryl esters. On the 
other hand, there is no evidence that EL would affect biliary sterol secretion. Therefore, the 
net effect of EL on reverse cholesterol transport remains speculative. (Yasuda, Ishida & 
Rader 2010). HL activity mainly affects the formation of nascent HDL particles from lipid-
rich forms of HDL. Since these nascent HDLs are effective acceptors of macrophage 
cholesterol, it could be hypothesized that HL enhances reverse cholesterol transport. HL 
deficiency has also been reported to raise HDL cholesterol but there is no increase in fecal 
excretion. (Rosenson et al. 2012). EL and HL, and their role in lipid metabolism are 
reviewed in more detail in chapter 2.3. 
2.2.5 Cholesterol biosynthesis 
The majority of cholesterol is synthesized endogenously. Cholesterol biosynthesis occurs 
primarily in the liver but also in other extrahepatic organs (intestine, adrenal glands) in a 
process that is regulated by several feedback inhibition steps. The biosynthetic pathway 
starts with the formation of acetoacyl-CoA from two moles of acetyl-CoA and subsequent 
formation of the key intermediate, HMG-CoA, by the enzyme HMG-CoA synthase. HMG-
CoA further undergoes reduction by HMG-CoA reductase to form mevalonate, which is 
the most regulated step in the pathway and is the target for cholesterol lowering drugs 
statins. Mevalonate is metabolized by a series of enzymes to form isopentenyl 
pyrophosphate (IPP), a basic unit for isoprenoid synthesis. IPP then polymerizes and 
produces farnesyl pyrophosphate (FPP). The formation of FPP can further lead to formation 
of both sterol and non-sterol products. The first step in sterol synthesis is the formation of 
squalene from FPP by squalene synthase. The cholesterol content of the cell regulates 
HMG-CoA reductase via negative feedback as well as via squalene synthase directing the 
flow of FPP either into the sterol or non-sterol pathway. Squalene is then converted into the 
first sterol, lanosterol, which further undergoes several oxidations, reductions and 
demethylations to form cholesterol. (Russell 1992). The cholesterol biosynthetic pathway is 
illustrated in Figure 6.  
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Figure 6. Cholesterol biosynthesis. Adapted from Russell (1992). 
 
2.2.5.1 Sterol regulatory element binding proteins 
Cholesterol homeostasis is regulated and maintained by following three feedback 
mechanisms: regulation of LDL receptor synthesis; regulation of HMG-CoA reductase and 
other enzymes in the biosynthetic pathway; and regulation of cholesterol 7-hydroxylase in 
bile acid synthesis (Russell 1992). Sterol regulatory element binding proteins (SREBPs) are 
basic-helix-loop-helix-leucine zipper transcription factors. They are responsible for the 
sterol-mediated transcriptional regulation of the HMG-CoA reductase and LDL receptor 
genes, as well as several other genes involved in cholesterol and fatty acid metabolism. 
(Horton et al. 2003). The first SREBP was identified as a protein that bound to sterol 
regulatory element (SRE) in the promoter of the LDL receptor gene (Briggs et al. 1993, 
Wang et al. 1993). Cloning of SREBP cDNAs revealed that there are three different SREBPs 
encoded by two SREBP genes. SREBP-1a and -1c arise from the same gene while SREBP-2 is 
derived from another gene. SREBP-1a and -1c transcripts are produced through the use of 
alternative transcription start site and differ in their first exon. SREBP-1a and SREBP-2 
proteins share 47% of homology. (Yokoyama et al. 1993, Hua et al. 1993). SREBP-1c was 
isolated independently and called adipocyte determination and differentiation dependent 
factor 1 for its role in adipogenesis (Tontonoz et al. 1993). SREBP-1c and SREBP-2 are 
predominantly synthesized in most of the tissues of human and mouse, whereas cultured 
cells produce primarily SREBP-1a and SREBP-2 (Shimomura et al. 1997b). 
SREBPs are synthesized as inactive precursors bound to the membrane of the 
endoplasmic reticulum (ER). They are regulated at three different levels: by activation 
through proteolytic cleavage of precursor forms, at the transcriptional level, and by post-
transcriptional modifications. In their inactive state, SREBPs form a complex with the 
SREBP cleavage activating protein (SCAP) and insulin-induced gene (Insig) and are 
anchored to the ER membrane. Upon activation signals, such as sterol depletion, SCAP-
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SREBP complex detaches from Insig and translocates to the Golgi, where the cleavage to the 
active mature forms of SREBPs occurs. This cleavage is mediated by two different 
proteases, site-1 (S1P) and site-2 protease (S2P). The mature forms of SREBPs are finally 
localized to the nucleus, where they regulate as homodimers the transcription of their 
target genes. (Sato 2010). The regulation by SREBPs occurs either via binding to the SREs or 
to the classic palindromic E-boxes (CAXXTG) (Kim et al. 1995). SREBP-1c possesses weaker 
transactivation potency than SREBP-1a due to a shorter transactivation domain (Shimano et 
al. 1997a), however, they both activate genes involved in the synthesis of fatty acids and 
their incorporation into triglycerides and phospholipids. SREBP-2 preferentially activates 
genes involved in cholesterol synthesis (Horton et al. 2003). The activation of SREBPs is 
illustrated in Figure 7.  
 
 
 
 
Figure 7. Activation of SREBPs. In basal conditions, SREBPs are inactive and bound to SCAP-
Insig complex on the ER membrane. Upon an activation signal, SREBP-SCAP complex detaches 
from Insig and translocates to the Golgi, where SREBPs are cleaved to mature forms by S1P and 
S2P. Finally, mature SREBPs are localized to the nucleus, where they regulate their target gene 
transcription. Modified from Sato (2009). 
2.2.6 Cholesterol lowering drugs 
Dyslipidemia is an important risk factor of atherosclerosis. It is defined by fasting serum 
LDL cholesterol exceeding 3.0 mmol/l, triglycerides 2.0 mmol/l and/or HDL cholesterol less 
than 1.0 mmol/l. Treatment of dyslipidemia primarily focuses on lowering total cholesterol 
and LDL cholesterol concentrations, targeting to values < 5.0 mmol/l for total cholesterol 
and < 3.0 mmol/l for LDL cholesterol. For patients at high risk for CVD, the target values 
are more stringent; total cholesterol < 4.5 mmol/l (with an option of < 4.0 mmol/l if feasible) 
and LDL cholesterol < 2.5 mmol/l (2.0 mmol/l if feasible). These high risk subjects include 
patients with markedly elevated single risk factors such as familial dyslipidemias and 
severe hypertension. In terms of the general population, the treatment of dyslipidemia 
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emphasizes lifestyle changes such as healthy diet, physical activity, smoking cessation and 
weight reduction. With patients at high risk of CVD the overall risk remains despite the 
lifestyle changes and drug treatment is often required. (Perk et al. 2012, Reiner et al. 2011). 
Total cholesterol and LDL cholesterol are primary targets of lipid-lowering therapy and 
HDL cholesterol is considered a secondary target. Although a variety of drugs can raise 
HDL levels, the overall effect on coronary risk or cardiovascular morbidity and mortality 
has not been established. (Perk et al. 2012, Hewing, Moore & Fisher 2012). Statins are the 
most effective and best-tolerated treatment option in cholesterol-lowering therapy. They 
inhibit HMG-CoA reductase in the liver leading to a decrease in cholesterol synthesis, an 
increase in the synthesis of LDL receptors and subsequent accelerated removal of LDL and 
triglyceride-rich lipoproteins (Gupta et al. 2010, Brown, Kovanen & Goldstein 1981). Statins 
can lower the LDL cholesterol by an average of 1.8 mmol/l (Anand 2003). With effective 
statin treatment it is possible to achieve almost physiological LDL cholesterol levels (1.5 
mmol/l; Goldstein, Brown 1977) that enable even regression of atherosclerotic lesions. The 
ASTEROID trial showed LDL cholesterol with an average of 1.6 mmol/l and direct 
ultrasound evidence of atheroma regression after two years of statin treatment (Nissen et 
al. 2006). In addition to lower LDL levels, a small increase in HDL cholesterol may occur 
after statin treatment. Furthermore, statins have been shown to improve endothelial 
function and plaque stabilization as well as to reduce C-reactive protein (CRP) and other 
markers of inflammation. (Ylä-Herttuala et al. 2013, Takemoto, Liao 2001). Moreover, the 
JUPITER trial of participants without hyperlipidemia but with elevated CRP showed that 
use of statins reduced the incidence of major cardiovascular events and death from any 
cause (Ridker et al. 2008). In general, statins are well tolerated and in clinical trials the 
reported adverse events are few. However, some side effects are reported, rhabdomyolysis 
and myopathy being the most serious ones (Silva et al. 2006). 
In addition to statins, there are also other lipid-lowering therapy options that can be 
used alone or in combination with statins. Bile acid sequestrants that bind bile acids in the 
intestine, preventing their absorption and reducing the hepatic pool of bile acids, can 
reduce LDL cholesterol by 15-30%. However, adverse gastrointestinal effects limit their use 
and they also can interfere with the absorbtion of other medications. The primary use of 
bile acid sequestrants is in combination therapy or as monotherapy for children with 
hypercholesterolemia. Fibrates increase the catabolism of triglycerides via LPL and 
decrease the production of triglyceride-rich lipoproteins by the liver also enhancing their 
clearance. They are often used in combination therapy or in patients that are not suited for 
statin treatment. However, when used in combination with statins, the risk of myopathy 
and several other milder side effects have been reported. Nicotinic acid (Niacin) reduces 
LDL cholesterol and triglycerides, and is the most effective drug for raising HDL 
cholesterol.  It also improves endothelial function and plaque stability as well as enhances 
clot lysis via increased fibrinolytic activity. However, in the case of niacin, there are also 
several side effects including flushing, gastric irritation, myopathy and increased blood 
glucose levels. (Gupta et al. 2010). Ezetimibe is the first drug that selectively inhibits 
cholesterol absorbtion from small intestine by blocking the Niemann-Pick C1-like protein 
receptor (Temel et al. 2007). Used alone its LDL cholesterol lowering efficacy is around 18% 
but in combination with statins the efficacy can increase to as high as 70%. Ezetimibe is also 
well tolerated. (Bruckert, Giral & Tellier 2003). 
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Based on recent clinical trials, inhibition of proprotein convertase subtilisin/kexin type 9 
(PCSK9) represents a new potent approach to lower LDL cholesterol. PCSK9 directly binds 
to LDL receptor inducing its degradation and subsequent increase in circulating LDL 
cholesterol. Loss-of-function mutations or genetic invalidation at the PCSK9 locus 
effectively lowered LDL cholesterol and reduced cardiovascular events almost up to 90%. 
Recent clinical trials using human PCSK9 antibodies blocking the PCSK9-LDL receptor 
interaction were shown to reduce LDL cholesterol levels by up to 65% when given alone 
and by up to 72% when combined with statin therapy. (Poirier, Mayer 2013). In addition, 
the use of PCSK9 antibodies was safe and well tolerated (Koren et al. 2013).  
Very recently, US Food and Drug Administration approved two novel lipid-lowering 
agents, lomitapide and mipomersen, for the management of homozygous familial 
hypercholesterolemia (FH). Lomitapide inhibits microsomal triglyceride transfer protein in 
the ER preventing formation of apoB-containing lipoproteins. Mipomersen is an antisense 
oligonucleotide that inhibits apoB-100 protein synthesis leading to reduced hepatic 
lipoprotein production.  Both agents have the ability to significantly lower LDL cholesterol 
and apo-B levels. However, it remains uncertain whether lomitapide and mipomersen will 
gain approval for use in patients with heterozygous FH or in the general population. Cost 
and concerns for the risk for transamine elevations and hepatic steatosis may remain the 
limiting factors to these agents being more widely used. (Dixon et al. 2013). 
2.2.7 Hyperlipidemic mouse models of atherosclerosis 
Mouse is the most often utilised species in studies of atherosclerosis and its complications. 
There are many advantages of working with mice such as relatively low cost of purchase 
and maintenance, ease of breeding and genetic manipulation, and the ability to monitor 
atherogenesis in a reasonable time frame. However, mouse and human also differ in several 
parameters that may influence atherogenesis. Wild type mice do not express CETP and a 
substantial fraction (~70%) of the VLDL secreted from the liver contains apoB-48 instead of 
apoB-100. Therefore, mice have a naturally high HDL and low LDL concentration and they 
are atherosclerosis-resistant. In addition, in mice that are genetically modified to form 
atherosclerotic lesions, the distribution and composition of the lesions are usually different 
compared to those formed in humans. At the moment there are a variety of genetically 
modified atherosclerotic mouse models available. Mouse models of atherosclerosis mostly 
depend on generating a non-HDL-based hypercholesterolemia. (Getz, Reardon 2012). Of 
those, following four different hyperlidemic mouse models of atherosclerosis will be 
reviewed here: ApoE-/- and LDLR-/- mice, mice deficient in both LDLR and apoE (LDLR-/-
ApoE-/-), and LDLR-/- mice only expressing apoB-100 (LDLR-/-ApoB100/100) (Table 2). 
ApoE-/- mice are probably the most widely used model in cardiovascular research. It was 
created simultaneously by two separate groups in 1992 through targeted gene inactivation 
(Piedrahita et al. 1992, Plump et al. 1992). On a regular chow diet, these mice have a total 
cholesterol level above 10 mmol/l. Cholesterol accumulates primarily in large apoB-48-
containing lipoprotein particles with a size corresponding to chylomicron remnants, VLDLs 
and IDLs, which are normally rapidly cleared via LRP and LDL receptor-mediated 
interaction with apoE in the liver. On a regular chow diet, ApoE-/- mice also develop 
complex cellular lesions comparable to human ones. (Zhang et al. 1992). After a high-fat 
diet atherogenesis is notably accelerated, characterized by lesions rich in lipids, and there is 
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a significant increase in plasma lipid levels (total cholesterol even 50 mmol/l) (Nakashima 
et al. 1994).  
LDLR-/- mice are also frequently used to study atherosclerosis. LDLR-/- model was created 
in 1993 by Ishibashi et al (1993). In this model, hyperlipidemia is milder than in ApoE-/- 
mice with total cholesterol only around 6.5 mmol/l on a regular chow diet. In addition, 
these mice do not develop lesions without a high-fat diet. LDL receptor deficiency leads to 
accumulation of apoB-100-containing particles mainly LDL. Genetic defects in the LDL 
receptor leading to hypercholesterolemia are also seen in humans with FH and in 
Watanabe-heritable hyperlipidemic (WHHL) rabbits. FH-patients and WHHL rabbits have 
massively elevated levels of IDL and LDL, and they develop atherosclerosis at an early age. 
In mice, LDL receptor deficiency is not that severe due to a more efficient apoE-mediated 
clearance of larger lipoproteins (VLDL and its remnants). In contrast in humans and rabbits 
these are mainly converted to LDL. However, in LDLR-/- mice the VLDL clearance is also 
reduced at some level since LDL receptor mediates this apoE-mediated clearance of apoB-
48-containing lipoproteins together with LRP. (Ishibashi et al. 1993). On a cholesterol rich 
diet (1.25% cholesterol), atherosclerosis is also accelerated in LDLR-/- mice with plasma 
cholesterol rising even above 50 mmol/l (Ishibashi et al. 1994). 
These two quite different models were also combined in 1994 by Ishibashi et al (1994). 
Lipoprotein profile of LDLR-/-ApoE-/- mice fed with a regular chow diet resembles 
lipoprotein profile seen in ApoE-/- mice. These mice also develop atherosclerotic lesions on a 
regular chow diet, total cholesterol being around 15 mmol/l. However, on a high-fat diet, 
hypercholesterolemia is more severe than in LDLR-/- or ApoE-/- mice alone. This is due to 
accumulation of both apoB-100 and apoB-48-containing lipoproteins. (Ishibashi et al. 1994). 
Even if these models mentioned above are frequently used, none of them has a 
lipoprotein profile resembling the one seen primarily in humans. In 1998 Veniant et al 
(1998) combined LDLR-/- mice with mice expressing only apoB-100. In these LDLR-/-
ApoB100/100 mice cholesterol is mostly carried in LDL particles and they also have low HDL 
cholesterol. In addition, like in humans, large lipoprotein particles (VLDL and its remnants) 
have apoB-100 as a major apolipoprotein. These mice develop extensive atherosclerosis 
already on a regular chow diet, total cholesterol being around 6.5 mmol/l. (Veniant et al. 
2000). Therefore, LDLR-/-ApoB100/100 mice are also better for modeling human FH. 
 
Table 2. Summary of the hyperlipidemic mouse models  
Mouse model Prominent 
lipoproteins 
TC (mmol/l) 
on a regular 
chow diet 
TC (mmol/l) 
on a high-fat 
diet 
Lesion 
development 
on a regular 
chow diet 
Reference 
ApoE-/- Remnants 
(ApoB-48) 
>10 ~50 Yes Piedrahita, 
1992; Plump, 
1992 
LDLR-/- IDL, LDL  
(ApoB-100) 
~6.5 ~50 No Ishibashi, 
1993 
LDLR-/-ApoE-/- Remnants 
(ApoB-48 and 
apoB-100) 
~15 >50 Yes Ishibashi, 
1994 
LDLR-/-ApoB100/100 LDL  
(ApoB-100) 
~6.5 nd Yes Veniant, 1998 
LDLR, LDL receptor; TC, total cholesterol; nd, not determined 
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2.3 VASCULAR LIPASES 
Lipases are water-soluble enzymes that hydrolyze the ester bonds of human water-
insoluble substrates. There are three different lipases in the vascular system: LPL, HL and 
EL (Table 3). They all belong to the triacylglycerol lipase family also known as LPL family. 
The main function of these secreted lipases is to hydrolyze triglycerides and phospholipids 
of circulating lipoproteins. Therefore, they are playing a central role as regulators of lipids 
trafficking in the vascular system. The effect of vascular lipases on atherosclerosis is still 
somewhat unclear, probably because all lipases have both anti- and pro-atherogenic effects 
depending on where they are expressed and what kind of models are used to study them. 
(Hasham, Pillarisetti 2006). 
There are many characteristic features that are shared between the vascular lipases. Their 
structure contains heparin and lipoprotein binding sites, catalytic triad and cysteine 
residues necessary for enzymatic activity (Jaye et al. 1999). Enzymatic activity also requires 
that native lipase monomers form a non-covalent mature homodimer in a process including 
different post-translational modifications (Griffon et al. 2009, Wang, Eckel 2009, Paterniti et 
al. 1983). After synthesis, vascular lipases are secreted and localized to the luminal surface 
of vascular endothelial cells, where they are attached to highly charged HSPGs to carry out 
their function in lipid metabolism (Jaye et al. 1999, Wang, Eckel 2009, Perret et al. 2002). 
Vascular lipases are also able to interact with lipoproteins independently of their lipolytic 
activity. This allows lipases to anchor lipoproteins to the vessel wall and facilitate 
lipoprotein particle uptake (so called bridging function). In addition, lipases can act as 
ligands for lipoprotein receptors leading to uptake of lipoproteins and selective uptake of 
lipoprotein associated lipids. (Qiu, Hill 2009, Wang, Eckel 2009, Zambon et al. 2003). 
 
Table 3. Summary of the features of lipases  
 Endothelial lipase Lipoprotein lipase Hepatic lipase 
Gene symbol LIPG LPL LIPC 
Size (kDa) 68 58 65 
Synthesis Vascular endothelial 
cells 
Parenchymal cells of 
heart, skeletal muscle 
and adipose tissue 
Hepatocytes 
Function A1 phospholipase Triglyceride hydrolase Triglyceride hydrolase, 
phospholipase 
Target lipoprotein HDL Chylomicron, VLDL Chylomicron remnants, 
IDL, LDL, HDL 
Tissues for lipoprotein 
function 
Endothelium Heart, muscle, adipose Liver 
 
2.3.1 Endothelial lipase 
EL, encoded by the LIPG gene, is the latest member of the triacylglycerol lipase family 
discovered in 1999 by two independent research groups (Jaye et al. 1999, Hirata et al. 1999). 
Mature EL is a 68 kDa glycoprotein (Miller et al. 2004), and it shares considerable homology 
with LPL (44%) and HL (41%) (Hirata et al. 1999). Many of the characteristic features of 
other family members are conserved in EL, however, it has a minimal sequence homology 
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in the lid domain, which determines substrate specificity. Also, in contrast to LPL and HL, 
EL is synthesized mainly by vascular endothelial cells, and to a lesser extent in 
macrophages and SMCs. In vivo, EL is expressed in various organs including placenta, lung, 
liver and kidney. (Jaye et al. 1999). 
EL possesses both triglyceridase and phospholipase activities, however, unlike LPL and 
HL, EL is primarily an A1 phospholipase and hydrolyzes HDL-phospholipids (McCoy et al. 
2002). Inverse correlation between HDL cholesterol and EL is well established indicating 
that EL is one of the major determinants of plasma HDL levels. Overexpression of human 
EL in mice has been shown to reduce plasma HDL cholesterol levels (Ishida et al. 2003, Jaye 
et al. 1999). Conversely, deletion of the functional LIPG gene via gene targeting (Ishida et al. 
2003, Ma et al. 2003) or inhibition of EL by inhibitory antibodies (Jin et al. 2003a) caused a 
significant increase in HDL levels in mice. The HDL particle size is increased in EL 
knockout mice, and turnover studies revealed a delayed clearance of HDL from the plasma 
in these mice (Ma et al. 2003). Also, different polymorphisms in the human LIPG gene have 
been suggested to be associated with plasma HDL cholesterol levels (Huang et al. 2010a). 
The expression of EL is highly regulated in vitro by proinflammatory cytokines (Hirata et 
al. 2000). In addition, EL has been shown to be directly upregulated by inflammation in 
humans (Badellino et al. 2008). There is some evidence that this upregulation occurs, at 
least partly, via NF-B, however these reports have been somewhat controversial (Jin et al. 
2003b, Kempe et al. 2005). EL activity is also regulated at the post-transcriptional level. 
Similar to LPL, this regulation occurs through a direct interaction with angiopoietin-like 
protein (ANGPTL) 3, lipase maturation factor (LMF) 1 and some specific proprotein 
convertases (Shimamura et al. 2007, Ben-Zeev et al. 2011, Jin et al. 2005, Essalmani et al. 
2013).  
2.3.2 Lipoprotein lipase 
LPL was discovered in 1943 (Hahn 1943) and it is the most studied member of the vascular 
lipases. The LPL gene encodes 448 amino acids that are highly conserved among mouse, 
human, and bovine species. LPL is synthesized in the parenchymal cells of the heart, 
skeletal muscle, as well as white and brown adipose tissues and it spreads along the 
vascular network to be localized to the luminal surface of vascular endothelial cells. (Wang, 
Eckel 2009). 
LPL is a triglyceride hydrolase that hydrolyzes core triglycerides of circulating 
triglyceride-rich lipoproteins, chylomicrons and VLDLs, generating fatty acids and 
monoacylglycerol that are either used for fuel in muscles or stored in the form of 
triglycerides in adipose tissue (Figures 3 and 4). In addition to releasing lipid nutrients for 
uptake by tissues, the lipolytic function of LPL produces atherogenic remnant lipoproteins, 
such as IDL, and provides lipids for biogenesis of HDL. (Wang, Eckel 2009). 
LPL protein consists of two distinct domains: an amino-terminal domain responsible for 
lipolysis and a carboxyl-terminal domain containing the heparin-binding region. LPL needs 
a specific cofactor, apoC-II, to be fully enzymatically active. The expression and activity of 
LPL is regulated at transcriptional, post-transcriptional, translational and post-translational 
levels in a tissue-specific manner. Firstly, there are several interacting proteins, such as 
ANGPTL3 and 4, LMF1 and glycosylphosphatidylinositol-anchored high-density 
lipoprotein-binding protein (GPIHBP) 1 that regulate LPL activity by several mechanisms 
(Lichtenstein, Kersten 2010, Peterfy et al. 2007). Secondly, hormonal and nutritional states 
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may affect the regulatory roles of interacting proteins or directly modify the regulation of 
LPL. And finally, LPL gene contains multiple regulatory elements for different 
transcription factors, which may participate in its regulation. (Wang, Eckel 2009, Davies et 
al. 2012). 
2.3.3 Hepatic lipase 
The human HL gene (LIPC) encodes a protein of 449 amino acids. HL is synthesized in the 
ER of hepatocytes as the preform and after post-translational modifications it is rapidly 
secreted as mature HL (mass around 65 kDa). The majority of HL is then bound to HSPGs 
on the surface of sinusoidal endothelial cells and the external surfaces of parenchymal cells 
in the space of Disse. However, it is noteworthy that in mice, there is high HL activity in the 
plasma suggesting that HL is mainly free in the circulation and not bound to cell surfaces. 
(Perret et al. 2002). 
HL possesses both triglyceridase and phopholipase A1 activities and therefore, 
contributes to the remodeling of chylomicron remnants, VLDL remnants, IDL, LDL and 
HDL. HL also interacts with lipoproteins by acting as a ligand for LRP promoting the 
hepatic uptake of lipoproteins. In addition, via its catalytic and ligand activities, HL 
contributes to the reverse cholesterol transport via HDL cholesteryl ester uptake. (Zambon 
et al. 2003). 
There are two inactive pools of HL in humans: HSPG-achored HL pool in the liver and 
HDL-bound circulating HL pool in the bloodstream. HDL is an important regulator of HL, 
it releases and activates HL in a process that is controlled by apoE and apoA in the HDL. 
(Chatterjee, Sparks 2011). Since HL needs to form homodimers to be fully active, also LMF1 
has been shown to regulate its activity (Paterniti et al. 1983). In addition, hormonal and 
nutritional changes have been reported to regulate either directly HL activity or its 
transcription via several putative regulatory elements, such as SRE and estrogen responsive 
element (Perret et al. 2002). 
2.3.4 Vascular lipases in atherosclerosis 
The role of EL in atherogenesis has been studied in two hyperlipidemic mouse models; 
ApoE-/- and LDLR-/- mice. Ishida et al (2004) reported that targeted EL inactivation increased 
HDL cholesterol and reduced atherosclerosis in ApoE-/- mice. In contrast, it was shown by 
Ko et al (2005) that EL inactivation did not affect atherogenesis in ApoE-/- and  
LDLR-/- mice despite raised HDL cholesterol. In addition, EL has been reported to promote 
the catabolism of atherogenic apoB-containing lipoproteins (Broedl et al. 2004). EL may also 
increase reverse cholesterol transport by redistributing cholesterol from the diseased vessel 
wall to the liver, subsequently affecting plaque formation (Yasuda, Ishida & Rader 2010). 
These findings imply that EL has some anti-atherogenic functions, however, it possesses 
also pro-atherogenic effects, especially locally at atherosclerotic lesions. EL has been shown 
to increase monocyte adhesion to the vessel wall (Kojma et al. 2004) as well as binding and 
uptake of native and oxidized LDL in macrophages via a so-called bridging function 
similar to LPL and HL (Qiu, Hill 2009). In addition, Azumi et al (2003) reported that EL is 
expressed in endothelial cells, SMCs and macrophages within human atherosclerotic 
lesions. 
LPL has also a dichotomous role in progression of atherosclerosis. Mice with targeted 
deletion of LPL gene were shown to develop spontaneous atherosclerosis (Zhang et al. 
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2008), whereas overexpression of human LPL in different animal models has been reported 
to lead to reduced atherosclerosis probably due to the reduction in remnant lipoproteins 
(Stein, Stein 2003). On the other hand, LPL was shown to be expressed by SMCs and 
macrophages in human and rabbit atherosclerotic lesions (Ylä-Herttuala et al. 1991). Also, 
studies with different animal models have shown that macrophage-derived LPL increases 
atherosclerosis (Stein, Stein 2003, Ichikawa et al. 2005). Furthermore, by acting as a 
molecular bridge between lipoproteins and cell surface or proteoglygans, macrophage-
derived LPL promotes LDL retention and extracellular lipid accumulation in the arterial 
intima (Pentikäinen et al. 2002). Finally, LPL is able to enhance monocyte adhesion to the 
endothelium (Mamputu, Desfaits & Renier 1997). 
Since HL hydrolyzes both triglycerides and phospholipids and also regulates lipid 
metabolism via its non-lipolytic functions, the role of HL in atherogenesis is probably the 
most complex of vascular lipases. HL overexpression beneficially alters lipid profile by 
reducing plasma apoB-containing lipoproteins (Dichek et al. 1998). On the other hand, 
lipolytic activity of HL produces highly atherogenic small dense LDL particles (Zambon et 
al. 2003). LDLR-/- mice either with normal HL or expressing catalytically inactive human HL 
only revealed reduced atherosclerosis compared to LDLR-/-HL-/- mice (Freeman et al. 2007, 
Qian, Agrawal & Dichek 2007). In contrast, HL deficiency in ApoE-/- (Mezdour et al. 1997) 
and LCAT transgenic mice (Nong et al. 2003) reduced atherosclerosis despite increases in 
plasma total cholesterol and apoB-containing lipoproteins. Furthermore, HL expressed only 
in macrophages enhanced early lesion formation in both ApoE-/- and LCAT transgenic mice 
(Nong et al. 2003). However, leukocyte-derived HL increased HDL and decreased 
atherosclerosis in LDLR-/- mice expressing human CETP (Hime et al. 2008). 
2.4 VASCULAR ENDOTHELIAL GROWTH FACTORS 
The VEGF family of ligands and receptors (Table 4) has a crucial role in vascular 
development and neovascularization in physiological and pathological processes. The 
VEGF family contains five following mammalian growth factors: VEGF-A (was also known 
as vascular permeability factor, VPF), VEGF-B, VEGF-C, VEGF-D and placental growth 
factor (PlGF). In addition, several non-vertebrate polypeptides with structural and 
functional similarities to mammalian VEGFs have been identified. These include Orf-virus 
derived VEGF-E and snake venom-derived VEGF-F. (Stuttfeld, Ballmer-Hofer 2009, Koch et 
al. 2011). 
Signaling of VEGFs is mediated by three receptor tyrosine kinases (RTKs): VEGF 
receptor (VEGFR)-1, VEGFR-2 and VEGFR-3. VEGFRs belong to the class V RTKs 
containing extracellular domain with immunoglobulin-like loops for ligand binding, a 
transmembrane domain, juxtamembrane domain, tyrosine kinase domains and a C-
terminal tail. Like with other RTKs, signaling of VEGFRs is initiated upon binding of VEGF 
ligand to the extracellular domain. This leads to receptor homo-heterodimerization 
followed by a phosphorylation of tyrosine kinase domains. As a result, several signaling 
molecules are recruited to VEGFR dimers and these large signal transduction complexes 
further activate distinct cellular pathways. Signaling via VEGFRs can also be modulated by 
VEGF-binding cell-surface expressed co-receptors; neuropilins (Nrps)-1 and -2. (Stuttfeld, 
Ballmer-Hofer 2009, Koch et al. 2011). 
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Table 4. Summary of VEGF receptors and their ligands. Adapted from Ylä-Herttuala et al (2007). 
Receptor Ligands Main functions 
VEGFR-1 VEGF-A, VEGF-B, PlGF Monocyte chemotaxis, endothelial cell 
organization, decoy function 
VEGFR-2 VEGF-A, VEGF-CNC, VEGF-
DNC, VEGF-E, VEGF-F  
Angiogenesis, survival, vascular permeability, 
proliferation 
VEGFR-3 VEGF-C, VEGF-D Lymphatic vessel growth 
 
Nrp-1 VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, PlGF 
Accessory function, endothelial cell survival 
Nrp-2 VEGF-A, VEGF-C, VEGF-D, 
PlGF 
Accessory function, capillary and lymphatic 
growth 
VEGF-C/DNC, proteolytically processed form of VEGF-C/D 
2.4.1 VEGF-A 
The first member of the VEGF family, VEGF-A, was originally found as a VPF secreted by 
tumor cells (Senger et al. 1983). In 1989 this same factor was purified as VEGF and further 
molecular cloning and expression studies of VPF and VEGF revealed that the two proteins 
were identical (Ferrara, Henzel 1989, Keck et al. 1989).  VEGF-A is expressed in almost all 
vascularized tissues, and via alternative splicing of VEGF-A mRNA different splice variants 
of VEGF-A are generated, VEGF-A165 being the predominant isoform (Maharaj et al. 2006, 
Ferrara, Gerber & LeCouter 2003). These isoforms have different molecular weight, heparin 
and heparan-sulfate binding properties as well as different affinities to the VEGFRs. VEGF-
A primarily mediates its effects by activating VEGFR-1 and VEGFR-2 but it also binds to 
Nrp-1 and Nrp-2 (Ferrara, Gerber & LeCouter 2003). 
VEGF-A is strongly regulated by hypoxia, hypoxia-inducible factor-1 mediating the 
responses. Other pathways including growth factors, inflammatory cytokines and 
hormones also regulate VEGF-A expression. (Ferrara, Gerber & LeCouter 2003). VEGF-A is 
a crucial factor for the development of vasculature. Even a single allele deficiency leads to 
embryonic lethality due to abnormal vascular development (Carmeliet et al. 1996). VEGF-A 
is also a key molecule regulating angiogenesis, vasculogenesis, and endothelial cell 
survival, proliferation and migration. VEGF-A increases permeability mainly by binding to 
VEGFR-2 leading to increased vascular leakage. (Ferrara, Gerber & LeCouter 2003). 
Furthermore, there has been some evidence that VEGF-A could also be involved in the 
regulation of lipid metabolism. VEGF-A has been shown to regulate SREBPs in human 
endothelial cells (Zhou et al. 2004). In addition, a common genetic regulation between 
VEGF-A and cholesterol homeostasis molecules was very recently reported (Stathopoulou 
et al. 2013). 
 
2.4.1.1 Role of VEGF-A in atherosclerosis 
The use of VEGF-A for therapeutic angiogenesis has been questioned due to concerns that 
VEGF-A could also enhance plaque neovascularization linked to growth and progression of 
atherosclerotic lesions (Ylä-Herttuala et al. 2007, Moreno et al. 2006). Although clinical trials 
so far have not shown any indications that VEGF-A promotes atherosclerosis or its clinical 
outcomes (Ylä-Herttuala et al. 2007), debate concerning the role of VEGF-A in atherogenesis 
continues probably due to inconsistent results from different animal studies. 
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In regards to the role of angiogenesis in atherosclerosis, it appears that reducing 
angiogenesis in the vessel wall slows down the growth of atherosclerotic plaques. 
Inhibition of intimal angiogenesis in ApoE-/- mice as well as vasa vasorum growth in LDLR-
/-ApoB100/100 mice has been shown to reduce atherosclerosis (Moulton et al. 1999, Drinane et 
al. 2009). However, in these studies the mechanisms were not specified to be directly VEGF-
related. Also, inhibition of VEGFR-2, a major mediator of VEGF-A-related angiogenic 
signals, has been shown to reduce atherosclerosis in LDLR-/- mice (Petrovan et al. 2007). In 
addition, VEGF-A is reported to be expressed in endothelial cells, SMCs and macrophages 
within human atherosclerotic lesions (Rutanen et al. 2003, Inoue et al. 1998). However, 
when it comes to direct effects of VEGF-A overexpression, the results have been more 
controversial. Celletti et al (2001b,a) reported enhanced atherosclerotic lesion formation 
after single injections of recombinant human VEGF-A165 in mice deficient in both apoE and 
apoB-100, and in New Zealand white rabbits. Furthermore, VEGF-A was proposed to 
increase monocyte activation, adhesion and migration (Celletti et al. 2001b). On the other 
hand, the role of VEGF-A in atherogenesis was challenged by Leppänen et al (2005), who 
showed that systemic adenoviral gene transfer with human VEGF-A165, as well as 
recombinant human VEGF-A165 administration in LDLR-/-ApoB100/100 mice, did not enhance 
atherosclerotic lesion formation, nor increased macrophage influx. Moreover, VEGF-A gene 
transfer has been shown to reduce intimal thickening in New Zealand white rabbit carotid 
arteries (Laitinen et al. 1997).  
2.4.2 Other VEGFs 
VEGF-B was isolated and characterized in 1996 and it has two different isoforms: heparin-
binding VEGF-B167 and freely soluble VEGF-B186 (Olofsson et al. 1996a, Olofsson et al. 
1996b). VEGF-B is highly expressed in tissues with high metabolic turnover such as heart, 
skeletal muscle and brown adipose tissue, and it is a ligand for VEGFR-1 and Nrp-1 
(Olofsson et al. 1996b). The precise role of VEGF-B in vivo was for a long time a mystery and 
still is somewhat unclear. Although VEGF-B-deficient mice are viable and fertile they were 
reported to develop smaller hearts and have impaired recovery after myocardial infarction 
(Bellomo et al. 2000). More recent findings have proposed a metabolic role for VEGF-B. 
VEGF-B167 overexpression was shown to result in cardiac lipid accumulation and 
subsequent malfunction of mitochondria (Karpanen et al. 2008). In addition, Lähteenvuo et 
al (2009) and Hagberg et al (2010) showed that VEGF-B can modify metabolic status of the 
heart and peripheral tissues. Later in 2012, it was shown by Hagberg et al (2012) that the 
effects of VEGF-B in fatty acid uptake may play a role in the development of insulin 
resistance and type 2 diabetes since the insulin sensitivity in rodent models of diabetes was 
restored by the inhibition of VEGF-B signaling. 
VEGF-C and VEGF-D are similar in structure and functional properties, and they are 
both secreted as precursor proteins that are further processed to the shorther forms  
(VEGF-CNC and VEGF-DNC). They both bind to VEGFR-3, Nrp-1, Nrp-2, and as fully 
processed forms to VEGFR-2. (Joukov et al. 1996, Joukov et al. 1997, Achen et al. 1998, 
Karpanen et al. 2006). VEGF-C, cloned in 1996, is mainly expressed in the heart, small 
intestine, placenta, ovary and thyroid gland (Joukov et al. 1996). It is primarily a 
lymphangiogenic growth factor and its lymphangiogenic effects are mediated by VEGFR-3 
(Enholm et al. 2001). VEGF-C deficiency in mice has been shown to be embryonically lethal 
(Karkkainen et al. 2004). VEGF-D, cloned in 1997, is most abundant in heart, skeletal 
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muscle, lung, colon and small intestine (Achen et al. 1998, Yamada et al. 1997). VEGF-D-
deficient mice are viable and fertile and display no pathological changes in lymphatic 
development (Baldwin et al. 2005). Via binding to VEGFR-2, VEGF-D is able to induce 
strong angiogenic and lymphangiogenic effects (Rissanen et al. 2003). 
PlGF was cloned from a human placental cDNA library in 1991 (Maglione et al. 1991). 
Four different isoforms of PlGFs have been described in human: PlGF-1, -2, -3 and -4. PlGF-
1 and -3 are soluble non-heparin-binding isoforms, whereas PlGF-2 and -4 bind to heparin 
(Cao et al. 1997, Yang et al. 2003). The effects of PlGFs are mediated by VEGFR-1, however, 
PlGF-2 is also able to bind Nrp-1 and Nrp-2 (Park et al. 1994, Migdal et al. 1998, Gaur et al. 
2009). PlGF mainly functions as a pro-angiogenic factor, regulated by hypoxia (Ziche et al. 
1997, Green et al. 2001). In addition, although PlGF-deficient mice were healthy and had a 
normal vasculature, they possessed increased permeability and impaired angiogenesis 
(Carmeliet et al. 2001). 
VEGF-E and VEGF-F are non-vertebrate proteins with structural and functional 
similarities shared with mammalian VEGFs. VEGF-E was identified in the genome of the 
parapoxvirus (Orf virus) in 1998 (Ogawa et al. 1998). It binds to VEGFR-2 and Nrp-1 and is 
able to stimulate endothelial cell growth and vascular permeability (Ogawa et al. 1998, 
Wise et al. 1999). In addition, VEGF-E containing PlGF-derived amino residues was shown 
to have angiogenic potency without the severety of side-effects seen with VEGF-A (Huusko 
et al., Zheng et al. 2006). VEGF-F was identified from snake venom quite recently 
(Yamazaki et al. 2005). It consists of at least two VEGF-related proteins, vammin and VR-1, 
which have 50% identity with VEGF-A165. VEGF-Fs bind to VEGFR-2 and heparin, and they 
increase endothelial cell proliferation and cause hypotension and vascular permeability 
(Yamazaki et al. 2005, Yamazaki et al. 2003, Matsunaga et al. 2009). 
2.4.3 VEGF receptors 
VEGFR-1, cloned in 1989 (Shibuya et al. 1989), is crucial for vascular development. VEGFR-
1 deficiency is embryonically lethal due to disorganization of blood vessels (Fong et al. 
1999). However, only the extracellular domain of the VEGFR-1 seems to be necessary for 
vascular development since mice with a deletion of the tyrosine kinase domain are healthy 
with a normal vasculature (Hiratsuka et al. 1998). VEGFR-1 is expressed in endothelial cells 
as well as in many non-endothelial cells such as pericytes, placental trophoblasts, vascular 
SMCs, monocytes and macrophages (Koch et al. 2011). The expression of VEGFR-1 is 
upregulated during angiogenesis and by hypoxia (Hiratsuka et al. 2001, Nomura et al. 
1995). It possesses weak mitogenic signaling properties, but it is known to form 
heterodimers with VEGFR-2 that has a strong signaling potency (Huang et al. 2001). 
Alternative splicing of VEGFR-1 produces soluble VEGFR-1 that is able to inhibit VEGF 
action (Kendall, Thomas 1993). 
VEGFR-2, identified in 1992 (Terman et al. 1992), is the primary receptor transmitting 
VEGF-A signals in endothelial cells (Koch et al. 2011). In addition to endothelial cells, 
VEGFR-2 is expressed in several non-endothelial cells such as pancreatic cells, 
megakaryocytes and hematopoietic cells (Koch et al. 2011). VEGFR-2 plays an important 
role in vasculogenesis and angiogenesis since mice deficient in VEGFR-2 have impaired 
vasculogenesis and disorganized vessel development (Shalaby et al. 1995). In addition, 
VEGFR-2 is shown to be expressed during pathological angiogenesis (Plate et al. 1993).  
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VEGFR-3 was identified in 1992 with a high structural similarity to VEGFR-1 
(Aprelikova et al. 1992). VEGFR-3 signaling is crucial for the development of vasculature 
during early embryonic stage but later the expression of VEGFR-3 becomes restricted to the 
developing lymphatic vessels (Dumont et al. 1998, Kaipainen et al. 1995). In adults, VEGFR-
3 has a primary role in lymphatic endothelial cells and in lymphangiogenesis (Koch et al. 
2011, Kaipainen et al. 1995). However, in adult tissues, VEGFR-3 is also highly expressed in 
the lung, heart and kidney, and its expression has been associated with angiogenesis and 
vascular network formation (Kukk et al. 1996, Tammela et al. 2008). 
Neuropilins, Nrp-1 and Nrp-2, are transmembrane receptors with a small cytoplasmic 
domain lacking a catalytic function. They are receptors for class 3 semaphorins and they 
also can act as co-receptors for VEGFRs modulating their signaling. Nrp-1 enhances VEGF-
VEGFR-2 interactions and signaling, and forms a heterodimer with VEGFR-2. (Koch et al. 
2011, Soker et al. 1998). Nrp-1 deficiency is embryonically lethal due to a variety of vascular 
abnormalities, and in developmental stage it is preferentially expressed in arteries 
(Fujisawa, Kitsukawa 1998, Eichmann, Makinen & Alitalo 2005). Nrp-2 forms a signaling 
complex with VEGFR-3 suggesting a role in lymphangiogenesis (Karpanen et al. 2006). 
Deficiency of Nrp-2 is not lethal but leads to abnormalities in small lymphatic vessels and 
capillaries, and during development it is mainly expressed in veins and lymphatic vessels 
(Eichmann, Makinen & Alitalo 2005, Yuan et al. 2002). 
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3  Aims of the study 
The aim of the thesis was to study the mechanisms of transcriptional regulation of EL and 
the role of VEGF-A in lipid metabolism. 
 
The specific aims of this thesis were as follows: 
 
 
I)  To analyze whether EL expression is modified by SFN treatment and to study 
NF-B-mediated regulation of EL. 
 
II) To investigate if EL is regulated by SREBPs and to analyze whether EL 
expression can be altered by VEGF-A with effects on HDL cholesterol levels. 
 
III) To analyze the effects of VEGF-A on lipoprotein metabolism and overall 
atherosclerosis in different mouse models of hyperlipidemia. 
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4  Materials and methods 
The materials and methods used in this study are summarized in the following tables (5-
11). Detailed descriptions of the methods are provided in the original publications (I-III). 
 
Table 5. Summary of the methods used in this study 
Method Description Original article 
Cell culture Cell line culture 
Human umbilical vein endothelial cell isolation 
I, II, II 
I, II 
DNA cloning Construction of vectors for adenoviral overexpression 
Construction of vectors for lentiviral overexpression 
III, unpub. 
I 
Production of 
lentiviral vectors 
Calcium phosphate transfection 
Ultracentrifugation for virus concentration 
Titer determination by FACS 
Titer determination by p24 
I 
I 
I 
I 
Production of 
adenoviral vectors 
Calcium phosphate transfection 
Ultracentrifugation for virus concentration 
Titer determination by plaque assay 
Titer determination by spectrophotometric analysis 
III, unpub. 
III, unpub. 
III, unpub. 
III, unpub. 
Cell biology methods Chemical treatment with compounds  presented in Table 8 
siRNA-transfection assay 
Viral vector transduction 
I, II, III 
II 
I, III 
Methods to study 
gene expression 
RNA isolation 
Quantitative real-time polymerase chain reaction (qPCR) 
I, II, III, unpub. 
I, II, III, unpub. 
Methods to study 
protein expression 
Measurement of total protein concentration 
Extraction of nuclear and cytoplasmic proteins 
Western blot 
Immunocytochemistry 
Enzyme-linked immunosorbent assay (ELISA) 
I, II 
I 
I, II 
I 
III, unpub. 
Protein-DNA 
interaction analysis 
Electrophoretic mobility shift assay (EMSA) 
Chromatin immunoprecipitation (ChIP) 
I 
I, II 
In vivo experiments Anesthesia, sacrifice, tissue and blood collection 
Intra vascular injection into tail vein 
II, III, unpub. 
II, III, unpub. 
Lipid metabolism 
analysis 
Measurement of plasma lipids 
Analysis of lipoprotein fractions by FPLC 
LPL activity assay 
II, III 
III 
III 
Evualuation of 
atherosclerosis 
Fixation, embedding, sectioning 
En face lesion analysis 
Cross-sectional lesion composition analysis 
III 
III 
III 
Computational 
analysis 
In silico promoter analysis (Genomatix) I, II, unpub. 
Statistical analysis Student´s t-test 
One-way ANOVA 
Pearson´s correlation coefficient 
I, II, III, unpub. 
I, II 
III 
HUVEC, Human umbilical vein endothelial cell; HAEC, Human aortic endothelial cell; FACS, Fluorescence-
activated cell sorting; FPLC, Fast protein liquid chromatography; unpub, unpublished results 
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Table 6. Cell lines and animal models used in this study 
 Description Origin Original article 
Cell line    
HUVEC Primary human endothelial cells from 
umbilical vein 
Kuopio University Hospital 
Maternity Ward 
I, II 
HAEC Primary human aortic endothelial 
cells 
Lonza I, II 
3T3-L1 Mouse embryonic fibroblast-adipose 
like cell line 
ATCC II, III 
Animal Model    
LDLR-/- LDLR receptor-deficient mouse in 
C57Bl/6J background 
The Jackson Laboratory III, unpub. 
LDLR-/-ApoB100/100 LDLR receptor-deficient mouse 
expressing only ApoB100 in C57Bl/6J 
background  
The Jackson Laboratory 
 
II, III, unpub. 
ApoE-/- ApoE-deficient mouse in C57Bl/6J 
background 
The Jackson Laboratory III, unpub. 
LDLR-/-ApoE-/- LDLR receptor and ApoE-deficient 
mouse in C57Bl/6J background 
The Jackson Laboratory III, unpub. 
 
Table 7. Viral vectors used in this study 
Plasmid Description Origin Original article 
LV-shp65 Human p65 silencing lentivirus with 
U6 promoter 
I. Verma I 
LV-IBM-GFP Lentivirus expressing mutated form of 
IB under mPGK promoter 
I. Verma I 
LV-IKK1-KD Lentivirus expressing mutated form of 
IKK1 under CMV promoter 
I. Verma I 
LV-IKK2-KM Lentivirus  expressing mutated form 
of IKK2 under CMV promoter 
I. Verma I 
AdVEGF-A165 Adenovirus expressing human  
VEGF-A165 under CMV promoter 
Werner Risau, Max Planck 
Institute, Germany  
II, III, unpub. 
AdLacZ Adenovirus expressing Escherichia 
coli LacZ under CMV enhancer and 
chicken -actin promoter 
A.I. Virtanen Institute II, III, unpub. 
AdCMV Empty adenovirus with CMV promoter A.I. Virtanen Institute III 
CMV, Cytomegalovirus; PGK, Phosphoglycerate kinase; up, unpublished results 
 
Table 8. Key reagents used in this study 
Compound Description Origin Original article 
TNF- Tumor necrosis factor- Sigma I 
SFN L-Sulforaphane Sigma I 
LPDS Lipoprotein-deficient serum By ultracentrifugation from 
FBS 
II 
25HC 25-Hydroxycholesterol Sigma II 
rhVEGF-A Recombinant human VEGF-A165 R&D Systems II, III 
SU1498 VEGF receptor-2 inhibitor LC Laboratories II 
FBS, Fetal bovine serum 
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Table 9. Primary antibodies used in this study 
Antibody Description Application Manufacturer Original article 
p50 Rabbit polyclonal anti-human 
Ab 
ChIP, EMSA Santa Cruz (#sc-7178) I 
p65 Rabbit polyclonal anti-human 
Ab 
ChIP, EMSA, 
ICC 
Santa Cruz (#sc-372) I 
EL Rabbit polyclonal anti-human 
Ab 
WB Abcam (#ab14797) I, II 
IB Rabbit polyclonal anti-human 
Ab 
WB Cell Signaling (#9242) I 
p-IB Rabbit monoclonal anti-
human Ab 
WB Cell Signaling (#2859) I 
IKK1 Rabbit polyclonal anti-human 
Ab 
WB Cell Signaling (#2682) I 
p-IKK1, 
p-IKK2 
Rabbit polyclonal anti-human 
Ab 
WB Cell Signaling (#2681) I 
IKK2 Rabbit polyclonal anti-human 
Ab 
WB Cell Signaling (#2684) I 
β-actin Rabbit polyclonal anti-human 
Ab 
WB Cell Signaling (#4967) I, II 
SREBP-1 Rabbit polyclonal anti-human 
Ab 
WB, ChIP Santa Cruz (#sc-8984) II 
SREBP-2 Mouse monoclonal anti-
human Ab 
WB Santa Cruz (#sc-13552) II 
SREBP-2 Goat polyclonal anti-human 
Ab 
ChIP Santa Cruz (#sc-8151) II 
mMQ Rabbit polyclonal anti-mouse 
Ab for macrophage detection 
IHC Accurate Chemical 
Scientific (#AIA31240) 
III 
ChIP, Chromatin immunoprecipitation; EMSA, Electrophoretic mobility shift assay; ICC, 
Immunocytochemistry; IHC, immunohistochemistry; WB, Western blot; Ab, Antibody 
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Table 10. DNA and RNA oligonucleotides used in this study 
Description Sequence/ Manufacturer Application Original article 
LIPG (-1250) primer GACTGCTGTG EMSA I 
LIPG (-1250) probe CCTGGGGAGGGAAAACCCCCACAGCAGTC EMSA I 
LIPG (521) primer GACTTGCCGG EMSA I 
LIPG (521) probe TGGTCTGATGGGGGCATTCCCGGCAAGTC EMSA I 
LIPG (2805) primer GATCCAGGGG EMSA I 
LIPG (2805) probe GTGGGGCCTGGGCTATTCCCCCTGGATC EMSA I 
LIPG (-8232) forward 
primer 
TTCAGAGACCGACCCTCAGGG ChIP I 
LIPG (-8232) reverse 
primer 
AGGATGTATGTCACCTCAGGACCC ChIP I 
LIPG (-1250) forward 
primer 
AAGCGTGCTCTGCTGGCAGC ChIP I 
LIPG (-1250) reverse 
primer 
GCTGCGCCAACAACCACTGC ChIP I 
LIPG (-466) forward 
primer 
AGCTAGTGGCGGAGCGAGC ChIP I 
LIPG (-466) reverse 
primer 
TCCCTGAAACTCTGCGTCCGC ChIP I 
LIPG (521) forward 
primer 
ACTTCTCTGTGCTGGGTCCC ChIP I 
LIPG (521) reverse 
primer 
GGTTCAGGCATGAGGACAAGG ChIP I 
LIPG (2805) forward 
primer 
TTTGGCAGCAAGACCTGG ChIP I 
LIPG (2805) reverse 
primer 
TGAAATGCTTGGGACCAGG ChIP I 
LIPG (-292) forward 
primer 
CCAGAGAGAGTGTGGCTTTGAGC ChIP II 
LIPG (-292) reverse 
primer 
CCAGCTTTCTCCCACTGCCC ChIP II 
LIPG (-1901) forward 
primer 
GGCTCTCAAGACACACTCTCC ChIP II 
LIPG (-1901) reverse 
primer 
TACTTGGGAGGCTGAGGC ChIP II 
LIPG (-2190) forward 
primer 
GCTGGGATCATAGGGATGCG ChIP II 
LIPG (-2190) reverse 
primer 
GTCCTGCAAAGTTAGTTATCCTGCC ChIP II 
SCAP-siRNA AACCUCCUGGCAGUAGAUGUA siRNA transfection II 
SREBP1-siRNA pool Dharmacon (#M-006891-01-0005) siRNA transfection II 
SREBP2-siRNA pool Dharmacon (#M-009549-00-0005) siRNA transfection II 
siControl Invitrogen (#12935-300) siRNA transfection II 
ChIP, Chromatin immunoprecipitation; EMSA, Electrophoretic mobility shift assay 
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Table 11. TaqMan gene expression assays used in this study 
Gene  TaqMan® Gene 
Expression Assay 
Original article 
LIPG Endothelial lipase Hs00195812_m1 
Mm00495368_m1 
I, II 
II 
B2M Beta-2-microglobulin Hs00187842_m1 I 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1 
4352932E 
I, II 
II, III 
SREBF1 Sterol regulatory element binding transcription 
factor 1 
Hs01088691_m1 II 
SREBF2 Sterol regulatory element binding transcription 
factor 2 
Hs01081784_m1 II 
SCAP SREBF chaperone Hs00378725_m1 II 
PPIA Peptidylprolyl isomerase A Hs99999904_m1 II 
LPL Lipoprotein lipase Mm00434770_m1 III 
LIPC Hepatic lipase Mm01171487_m1 III 
LIPE Hormone sensitive lipase Mm00495359_m1 III 
ANGPTL3 Angiopoietin-like 3 Mm00803820_m1 III 
ANGPTL4 Angiopoietin-like 4 Mm00480431_m1 III 
LMF1 Lipase maturation factor 1 Mm00512942_m1 III 
GPIHBP1 GPI-anchored HDL-binding protein 1 Mm01205849_g1 III 
Hs, human; Mm, mouse; m1, mRNA; g1, genomic 
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5  Results 
5.1 REGULATION OF ENDOTHELIAL LIPASE BY SULFORAPHANE AND  
NF-B (I) 
5.1.1 Endothelial lipase is regulated via the classical NF-B pathway 
EL is known to be regulated by inflammatory cytokines and inflammation mediated at least 
partly through NF-B. To study NF-B-mediated regulation of EL in more detail, human 
umbilical vein endothelial cells (HUVECs) were first treated with TNF- which increased 
EL mRNA expression in a concentration- and time-dependent manner (Figure 8A and B, I). 
The activation and translocation of NF-B dimers to the nucleus is preceded by 
phosphorylation of IKK complex and IB-. Hence, HUVECs were transduced with 
dominant negative mutant of IB- (IBM) which led to a 67% decrease in EL expression 
after exposure to TNF- (Figure 8C, I). Similarly, silencing of NF-B subunit p65 using 
RNA interference decreased EL expression by 61% (Figure 8C, I). Furthermore, 
overexpression of kinase activity-deficient form of IKK2 (IKK2-KM) suppressed EL 
expression by 31% and together with kinase activity-deficient form of IKK1 (IKK1-KD) by 
67% (Figure 8C, I). Therefore, it is evident that NF-B via its classical regulatory pathway 
controls the transcriptional regulation of EL. 
 
 
Figure 8. EL expression is regulated by TNF- via the classical NF-B pathway. HUVECs were 
treated with 0-40 ng/mL TNF- for 24 h (A) or with 10 ng/mL TNF- for 0-48 h (B). EL 
expression after transduction with LV-IBM-GFP, LV-shp65, LV-IKK1-KD and LV-IKK2-KM and 
treatment with TNF- (4 ng/mL, 24 h). EL mRNA expression analyzed by qPCR was normalized 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Each bar represents mean ± SD 
(n=3-4). *P<0.05, **P<0.01, ***P<0.001 versus control. 
5.1.2 Sulforaphane inhibits TNF--induced endothelial lipase expression 
EL is a major regulator of HDL levels and therefore, reduced EL levels are desirable. Since 
NF-B is reported to be a molecular target for SFN-mediated anti-inflammatory and anti-
carcinogenic effects, the effects of SFN on EL expression were studied. Treatment of 
HUVECs with SFN reduced EL mRNA in a concentration- and time-dependent manner 
(Figure 9A and B, I). In addition, SFN was able to diminish TNF--induced EL expression 
(Figure 9C and D, I). To study, whether the effects of SFN on EL expression were 
dependent on NF-B, the binding of the NF-B subunits to the LIPG gene was assessed 
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using the ChIP assay (Figure 9E, I) and EMSA analysis (I). Altogether, five binding sites of 
NF-B, two published earlier and three novel binding sites, seemed to bind either p65, p50 
or both subunit of NF-B after treatment with TNF- and this binding was inhibited by 
SFN (Figure 9E, I).  
 
 
 
Figure 9. SFN inhibits EL expression through NF-B. HUVECs were treated with 0-10 µmol/L SFN 
for 16 h (A) or with 10 µmol/L SFN for 0-24 h (B). The expression of EL mRNA (C) and protein 
(D) after TNF- (4 ng/mL) and SFN (10 µmol/L) treatment. EL mRNA expression analyzed by 
qPCR was normalized to GAPDH. Each bar represents mean ± SD (n=3). *P<0.05, ***P<0.001 
versus control. The binding of NF-B to the LIPG gene after TNF- (4 ng/mL, 3 h) and SFN (10 
µmol/L, 4h) treatment determined by ChIP followed by PCR for specific sites of LIPG gene (E). 
Chromatin was precipitated either with specific anti-p65 or anti-p50 antibodies or IgG as a 
control. 
 
SFN inhibited NF-B activity via various mechanisms. SFN decreased the phosphorylation 
of IKK1, IKK2 and IB- after TNF- treatment (I). In addition, SFN reduced TNF--
induced nuclear localization of NF-B subunit p65 (I). Taken together, SFN may have 
vasculoprotective effects not only via its anti-inflammatory properties, but additionally via 
inhibition of EL. 
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5.2 REGULATION OF ENDOTHELIAL LIPASE BY STEROL REGULATORY 
BINDING PROTEINS (II) 
The regulation of EL has been mainly attributed to inflammatory stimuli. SREBPs are well 
known regulators of genes involved in lipid metabolism such as LPL and therefore, the role 
of SREBPs in the transcriptional regulation of EL was studied. In the presence of sterols, 
SREBPs are anchored as a complex with SCAP on the ER membrane. Activation signals, 
like sterol depletion, release SREBP-SCAP complex from the ER membrane, after which this 
complex is further cleaved to the active forms of SREBPs in the Golgi. The mature forms of 
SREBPs localize to the nucleus where they regulate transcription of their target genes. First, 
HUVECs were treated with lipoprotein-deficient serum (LPDS) which increased both the 
mRNA and protein levels of EL (II). The possible role of SREBPs in EL regulation was 
further investigated using 25HC, an inhibitor of SREBP activation, and specific siRNAs 
against SREBP-1, SREBP-2 and SCAP. 25HC was able to reduce EL mRNA expression both 
in basal conditions and after LPDS treatment (Figure 10A, II). Combined inhibition of 
SREBP-1 and -2 reduced EL basal expression and a similar result was obtained by inhibition 
of SCAP (Figure 10B, II). Starvation-induced EL expression appeared to be SREBP-2 and 
SCAP dependent since siRNA-mediated inhibition of SREBP-2 or SCAP blocked EL 
induction by LPDS (Figure 10C, II). This was not totally surprising since SREBP-2 is more 
specific for sensing sterol balance in the cells (Eberle et al. 2004). 
 
Figure 10. EL is regulated through SREBPs in endothelial cells. EL mRNA levels after 25HC (1 
µg/mL, 3 h) in normal serum and after LPDS (A). EL mRNA levels after siRNA-mediated 
inhibition of SREBP-1 (F1) and SREBP-2 (F2) alone or in combination, and SCAP in normal 
serum (B) and after LPDS (C). EL mRNA expression analyzed by qPCR was normalized to PPIA. 
Each bar represents mean ± SD (n=3-6). *P<0.05, **P<0.01, ***P<0.001 versus no 
treatment (nt) control. Bars above columns indicate additional comparisons. 
 
The binding of SREBP-1 and -2 to the SREBP binding sites in LIPG gene was also studied in 
normal conditions and after LPDS using the ChIP analysis. LPDS-induced the binding of 
SREBP-2 to the LIPG gene and this binding was inhibited by 25HC (II). Evidently, SREBPs, 
and especially SREBP-2, are involved in the transcriptional regulation of EL, indicating that 
systemic cholesterol levels could regulate EL levels in the endothelial lining of blood 
vessels. 
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5.3 THE EFFECTS OF VEGF-A ON LIPID METABOLISM AND 
ATHEROSCLEROSIS IN HYPERLIPIDEMIC MOUSE MODELS (II, III AND 
UNPUBLISHED RESULTS) 
5.3.1  VEGF-A increases atherosclerosis only in apoE-deficient models 
The role of VEGF-A in atherogenesis has remained controversial due to inconsistent results 
reported from animal studies. We addressed this by comparing the effects of adenoviral 
VEGF-A (AdVEGF-A) gene transfer on atherosclerosis in ApoE-/-, LDLR-/-, LDLR-/-ApoE-/- 
and LDLR-/-ApoB100/100 mice. The lesion area was examined en face one month after gene 
transfer and a total Western diet period of 2.5 months. Enhanced lesion development was 
observed in thoracic and abdominal aortas after AdVEGF-A gene transfer in apoE-deficient 
models; the effect of VEGF-A on lesion area was statistically significant only in ApoE-/- mice 
with a similar tendency in the LDLR-/-ApoE-/- group (Figure 11, III). However, no changes in 
lesion morphology after AdVEGF-A gene transfer were noticed in different mouse models 
(III). 
 
 
 
Figure 11. VEGF-A enhances lesion development in apoE-deficient mice. Aortic en face lesion 
areas of LDLR-/- (A), ApoE-/- (B), LDLR-/-ApoB100/100 (C) and LDLR-/-ApoE-/- mice (D). Aortic en 
face lesion areas of ApoE-/- (E) and LDLR-/-ApoE-/- mice (F) one month after AdVEGF-A gene 
transfer. Quantification (%) of en face lesion areas of different mouse models (G). Values are 
represented as mean ± SD, n=6-10 per group. *P<0.05 versus control.  Fig 2.1 sections from the mice fed Western type basic diet ( FAT) 
Fig 2.2 sections from the mice fed vitamin E and C supplemented basic diet  ( EC) 
Fig 2.3 sections from the mice fed Western type basic diet and mercury suppl. 
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5.3.2  VEGF-A induces alterations in lipid profiles and plasma lipids 
In order to examine whether the pro-atherogenic effects of VEGF-A observed in apoE-
models would be caused by changes in plasma lipids, lipoprotein profiles and plasma 
levels of cholesterol, triglycerides and HDL were investigated. In general, AdVEGF-A gene 
transfer increased the triglyceride proportion in large VLDL particles (III). However, as 
compared to the other models the LDLR-/-ApoB100/100 mice had a decreased proportion of 
cholesterol in VLDL particles and clearly an increased proportion of phospholipids in HDL 
(III). In addition, 14 days after AdVEGF-A gene transfer, LDLR-/-ApoB100/100 and  
LDLR-/- mice had elevated plasma levels of total cholesterol and HDL compared to control 
mice (Figure 12A-D, II, III, data not shown).  
 
 
Figure 12. VEGF-A increases plasma levels of total cholesterol and HDL in LDLR-/-ApoB100/100 and 
LDLR-/- mice. Plasma total cholesterol (A-B) and HDL cholesterol (C-D) 14 days after AdVEGF-A 
gene transfer. The results for individual mice are presented as scatter plots and the average of 
each group is indicated as a horizontal bar +SD. *P<0.05, **P<0.01 versus control.  
5.3.3  VEGF-A inhibits vascular lipases in vitro and in vivo 
To find an explanation for the changes seen in the lipid profiles and plasma lipids, plasma 
LPL activity was measured four days after AdVEGF-A gene transfer. Interestingly, 
AdVEGF-A reduced post-heparin plasma LPL activity in ApoE-/-, LDLR-/-ApoE-/- and  
LDLR-/-ApoB100/100 mice compared to AdLacZ control mice (III). In addition, a significant 
negative correlation between plasma LPL activity and human VEGF-A (hVEGF-A) levels 
was observed in all models (Figure 13A-D, III). 
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Figure 13. VEGF-A reduces plasma LPL activity. Plasma VEGF-A and LPL activity four days after 
VEGF-A gene transfer in LDLR-/- (A), ApoE-/- (B), LDLR-/-ApoB100/100 (C) and LDLR-/-ApoE-/- (D) 
mice. The degree of the association was measured by Pearson’s correlation coefficient (r).  
 
Furthermore, tissue expression of different vascular lipases in LDLR-/-ApoB100/100 mice was 
investigated. AdVEGF-A reduced LPL mRNA in the heart and white adipose tissue (WAT) 
(Figure 14A and B, III). EL mRNA levels were reduced in the liver and WAT (Figure 14C 
and D), whereas HL mRNA levels remained unchanged (II, III). Since a reduction in LPL 
mRNA or protein levels does not necessarily correlate with the enzyme activity, we also 
looked into other possible mechanisms of interaction by measuring the expression of 
ANGPTL3, ANGPTL4, LMF1 and GPIHBP1, genes that are known to regulate LPL activity 
in a post-translational manner. Surprisingly, AdVEGF-A significantly increased the 
ANGPTL4 mRNA levels in the heart and WAT compared to control (Figure 14E and F), 
whereas expression of other genes remained unchanged (III). These findings were also 
confirmed in vitro using 3T3-L1 preadipocytes, where recombinant human VEGF-A 
reduced LPL mRNA and increased ANGPTL4 mRNA levels (III). VEGF-A was not able to 
inhibit EL mRNA expression in 3T3-L1 cells (II) which is most probably due to a lack of 
VEGFR-2 in these cells. In contrast in HUVECs, EL expression was decreased by VEGF-A 
and the effect was abolished when VEGFR-2 was inhibited by a specific inhibitor SU1498 
(II). Therefore, it seems that VEGF-A regulates transcriptional expression of LPL and EL via 
two different receptors: LPL via VEGFR-1 and EL via VEGFR-2 (II, III). 
The transcriptional regulation of EL by VEGF-A was also studied in more detail in 
HUVECs (II). VEGF-A inhibited EL mRNA and protein expression after LPDS treatment, 
and since VEGF-A has been shown to regulate SREBP activation, the role of SREBPs in EL 
regulation by VEGF-A was investigated. VEGF-A was able to inhibit LPDS-induced 
binding of SREBP-2 to three different SREBP binding sites in LIPG gene suggesting that the 
effects of VEGF-A were mediated by SREBP-2 (II). However, VEGF-A also seemed to 
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activate and increase the binding of SREBP-1 (II), but the effect on EL expression remained 
somewhat unclear. 
 
 
 
Figure 14. VEGF-A reduces LPL and EL mRNA and increases ANGPTL4 mRNA expression. LPL 
mRNA expression in the heart (A) and WAT (B). EL mRNA expression in the liver (C) and WAT 
(D). ANGPTL4 mRNA expression in the heart (E) and in WAT (F). mRNA expression levels of 
LDLR-/-ApoB100/100 mice were analyzed by qPCR and normalized to GAPDH. The results for 
individual mice are presented as scatter plots and the average of each group is indicated as a 
horizontal bar + SD. *P<0.05, ***<0.001 versus control.  
 
5.4 MOUSE MODEL-SPECIFIC DIFFERENCES IN ADENOVIRAL GENE 
THERAPY (III AND UNPUBLISHED RESULTS) 
Although the same amount of virus was used in all models, the plasma levels of hVEGF-A 
on a Western type diet (WTD) (21% fat, 0.15% cholesterol) were significantly lower in 
LDLR-/- and LDLR-/-ApoB100/100 mice compared to apoE-deficient models (Figure 15A, III). 
When compared to C57Bl/6 mice, apoE-deficiency also seemed to reduce plasma transgene 
expression (Figure 15A, data not shown). This could be due to some lipid-virus 
interactions; it has been suggested that adenoviruses are able to use LRP and HSPGs for 
entry into the cells, an uptake mechanism competed by increased plasma lipid levels 
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(Shayakhmetov et al. 2005). Therefore, plasma levels of hVEGF-A were also measured 
without a WTD. Indeed, higher plasma lipid levels seemed to be protective against viral 
infection since on a regular chow diet, plasma VEGF-A levels were higher compared to 
levels on a WTD in all LDLR-deficient models (Figure 15B, data not shown). However, in 
C57Bl/6 and apoE-/- mice there was no difference in hVEGF-A levels on a WTD compared to 
levels on regular chow diet (Figure 15B, data not shown). Similar results were seen when 
the liver hVEGF-A mRNA expression levels were compared either between different 
strains or diets (Figure 15C, data not shown). Importantly, the high plasma levels of 
hVEGF-A on a WTD were seen in the same models also with increased atherosclerosis 
(Figure 11). Furthermore, the high expression of the transgene, most likely due to a more 
efficient intake of the virus leading to better transduction efficiency, caused a typical VEGF-
A-related response in the mice. Histological analysis showed dilatation of the capillaries in 
all inspected tissues (liver, heart, spleen, lung and kidney) (data not shown). As expected, 
the angiogenic response was the most prominent and adverse in the livers of the animals 
with high VEGF-A expression causing lacuna-like vessels and leading to a decreased 
survival of the animals (Figure 15D, data not shown).  
 
 
Figure 15. Differences in transduction efficiency and survival of mice in different mouse models 
after systemic AdVEGF-A gene transfer. Plasma hVEGF-A expression four days after gene 
transfer in different mouse models on a WTD (A-B) and on a regular chow diet (B). Liver 
hVEGF-A mRNA expression four days after gene transfer in different mouse models (C). Survival 
of mice after AdVEGF-A gene transfer (D). hVEGF-A mRNA expression levels were analyzed by 
qPCR and normalized to peptidylprolyl isomerase A (PPIA). *P<0.05, **P<0.01, ***<0.001  
versus control or matched diet.  
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6  Discussion 
6.1 TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL LIPASE 
Extensive evidence supports the protective role of HDL against coronary heart disease and 
atherosclerosis (Wang, Briggs 2004). Due to its cellular cholesterol efflux capacity and anti-
oxidative activity, high levels of HDL can protect vasculature from lipid stress. EL is a 
major determinant of HDL cholesterol levels and in inflammatory states, like 
atherosclerosis, EL expression is increased contributing to low HDL. Therefore, therapies 
aiming at reducing EL levels are of great interest. However, the regulation of EL expression 
is poorly understood and has mainly been focused on inflammatory stimuli.  
EL is regulated at the transcriptional level by cytokine stimuli and there is some evidence 
that this regulation occurs, at least partly, via NF-B. However, these reports have been 
somewhat controversial. (Jin et al. 2003b, Kempe et al. 2005). This current study provides 
more detailed evidence that EL is regulated at the transcriptional level by the classical NF-
B activation under inflammatory stimuli (Figure 16, I, II). Both mutated form of IB- as 
well as lentiviral siRNA against p65 revealed a marked reduction in EL expression after 
TNF- treatment indicating that NF-B plays an important role in EL regulation, which is 
in agreement with earlier studies (Jin et al. 2003b, Kempe et al. 2005). It has been thought 
that the role of IKK1 in classical NF-B pathway is dispensable, however, the results in the 
current study suggest that either IKK1 or IKK2 can mediate the signaling since blunting of 
only one kinase did not abolish the EL induction. This is in agreement with an observation 
by Luedde et al (2008) who showed that IKK1 and IKK2 can cooperate and share a 
redundant function of mediating lipopolysaccharide/TNF- challenged NF-B signaling. In 
addition, it was shown recently that IKK1 is critical for efficient cytokine-induced NF-B 
activation in the classical pathway (Adli et al. 2010). 
The results of the current study also showed that SFN, a member of the isothiocyanate 
class of compounds found in cruciferous vegetables, was able to decrease EL expression via 
NF-B in endothelial cells (Figure 16, I, II). This suggests that SFN could have vasculo-
protective effects not only via its anti-inflammatory properties but also via beneficial effects 
on lipid metabolism. SFN reduced EL expression already at micromolar concentrations. 
Previous studies have shown that similar micromolar concentrations are also attainable in 
vivo after oral administration of SFN in humans and rats (Riedl, Saxon & Diaz-Sanchez 
2009, Hu et al. 2004). However, when plasma lipid levels were studied after intake of SFN 
or broccoli sprouts, rich in glucosinolate precursor forms of SFN, the results were more 
controversial. It was shown that ingestion of broccoli sprouts increased plasma HDL 
cholesterol and decreased the levels of total cholesterol as well as LDL cholesterol in 
diabetic humans and hyperlipidemic rats (Murashima et al. 2004, Lee et al. 2009). In 
contrast, ingestion of broccoli sprouts powder in hypertensive humans (Christiansen et al. 
2010) or oral administration of SFN in diabetic rats (Souza et al. 2013) had no effects on 
plasma levels of HDL, LDL and total cholesterol. Nevertheless, there is strong evidence that 
dietary interventions have beneficial effects on plasma lipid levels and cardiovascular 
health. It is unclear, whether the observed positive effects are due to a single compound or 
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the synergistic effects of multiple compounds (Rodriguez-Cantu et al. 2011). In addition, 
cholesterol and lipid homeostasis is affected by sex, due in part to the influence of sex 
hormones on the regulation of metabolic pathways. In case of SFN, another mechanism in 
relation to the lipid-lowering effects may be associated with the capacity to induce the Nrf2 
pathway and subsequent regulation of lipogenic genes such as peroxisome proliferator-
activated receptor  (Huang et al. 2010b). 
The current study also identifies SREBPs as novel transcriptional regulators of EL. 
Altogether, three novel binding sites for SREBP-1 and SREBP-2 were predicted in LIPG 
gene promoter area using Genomatix in silico promoter analysis and binding of SREBPs to 
these sites was investigated using ChIP analysis. Both SREBP-1 and SREBP-2 were able to 
bind to these sites and 25HC inhibited this binding as expected. SREBP-2 as a more specific 
sensor for cholesterol changes in the cells was mediating LPDS-induced regulation of EL. 
Similar results were obtained when specific siRNAs against SREBP-1, SREBP-2 and SCAP 
were used. Unexpectedly, when siRNAs against SREBP-1 or SREBP-2 alone were used in 
basal conditions, EL mRNA expression was increased. However, the inhibition of one 
SREBP also increased the expression of the other SREBP suggesting some kind of reciprocal 
regulation of SREBPs which could at least partly explain the increased EL expression. It has 
been shown in vivo that at least SREBP-2 is able to replace SREBP-1 to some extent in 
regulating cholesterol synthesis since targeted disruption of the SREBP-1 gene leads to 
elevated levels of liver SREBP-2 expression and cholesterol synthesis in mice (Shimano et 
al. 1997b). In addition, for reasons that are still unclear, the inhibition of both SREBP-1 and  
-2 in combination was not able to inhibit LPDS-induced EL expression. It could be possible 
that in LPDS-induced conditions blocking of both SREBPs activates some other signaling 
pathways involved in EL regulation. In the current study, the protein levels of SREBPs were 
not measured. It has been shown previously that there are differences between mRNA 
levels and protein accumulation in the nucleus for both SREBP-1 and -2 and therefore, 
changes in mRNA levels may not reflect the same trend in protein accumulation or activity 
(Shimomura et al. 1997a). Nevertheless, it was recently postulated that the cellular 
cholesterol content may regulate hepatic EL expression via a mechanism that is still 
unknown (Yasuda, Ishida & Rader 2010).  The results of the current study indicate that 
SREBPs, especially SREBP-2, clearly have a role in the regulation of EL and they could 
respond to cholesterol changes via regulation of EL (Figure 16, I, II). 
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Figure 16. Transcriptional regulation of EL by NF-B and SREBPs in endothelial cells based on 
the results presented in this thesis. TNF- activates the classical NF-B pathway leading to 
increased expression of EL. SFN reduces NF-B activity by inhibiting IKK1, IKK2 and IB- 
phosphorylation as well as nuclear localization and binding of NF-B subunits to LIPG promoter 
subsequently leading to reduced EL expression. EL expression is also regulated by SREBPs 
which upon activation translocate to the nucleus and initiate EL transcription. VEGF-A reduces 
EL expression by inhibiting SREBP2 binding to LIPG promoter leading to a subsequent increase 
in HDL cholesterol. 
 
6.2 THE ROLE OF VEGF-A IN LIPID METABOLISM AND 
ATHEROSCLEROSIS 
The role of VEGF-A in atherogenesis has remained controversial. The current study 
addressed this by comparing the short-term effects of AdVEGF-A gene transfer in four 
different mouse models of hyperlipidemia. The results demonstrate that VEGF-A induces 
changes in lipoprotein profiles and plasma lipids as well as decreases LPL activity in all 
studied models (Figure 17, III). However, the overexpression of VEGF-A increases 
atherosclerosis only in apoE-deficient models (Figure 17, III) suggesting that the use of 
different mouse models for studying the role of VEGF-A in atherogenesis is likely one 
major factor explaining the contradictory results seen in the literature. 
The negative correlation between plasma LPL activity and hVEGF-A levels was an 
unexpected finding. Although, VEGF-A decreased LPL activity in all studied models,  
LDLR-/- and LDLR-/-ApoB100/100 mice appeared to be more sensitive to the decreased LPL 
activity than apoE-deficient models. When looking into the lipid profiles, an increase in 
triglyceride proportions in VLDL particles was observed and the increase was the largest in 
LDLR-/-ApoB100/100 mice. In addition, unlike apoE-deficient mice, both LDLR-/- and LDLR-/-
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ApoB100/100 mice showed significantly increased total cholesterol levels 14 days after 
AdVEGF-A gene transfer. LDLR-/-ApoB100/100 mice also had an increased proportion of 
phospholipids in HDL, and like in LDLR-/- mice, increased levels of plasma HDL, this was 
probably due to inhibition of EL. However, increased atherosclerosis after AdVEGF-A was 
only seen in models lacking apoE. Therefore, it seems that the lipid changes following a 40-
60% decrease in LPL activity are not enough to affect atherogenesis in the LDLR-/- models. 
This is not totally surprising, since in human subjects heterozygous for the LPL gene, a 30-
50% decrease in LPL activity causes only a modest elevation of plasma triglycerides 
concentrations and not even any changes in total cholesterol (Ooi et al. 2012, Nordestgaard 
et al. 1997). In addition, it seems that the reduction in LPL activity was unlikely to play a 
significant role in the increased atherosclerosis of the apoE-deficient models, leaving it open 
whether some other VEGF-mediated effects influenced atherogenesis in these strains. 
Actually, in ApoE-/- mice, VEGF-A was reported to increase plaque angiogenesis leading to 
increased atherosclerosis (Celletti et al. 2001b). However, this was not seen in the study by 
Leppänen et al (2005) with LDLR-/-ApoB100/100 mice and systemic AdVEGF-A administration. 
In addition, apoB-100-containing lipoproteins have been shown to be able to inhibit 
angiogenesis via VEGFR-1 (Avraham-Davidi et al. 2012). Since LDLR-/- and  
LDLR-/-ApoB100/100 mice have six- and nine-fold higher plasma levels of apoB-100 particles 
compared to ApoE-/- mice (Veniant et al. 1998), they could be protected against VEGF-A-
induced angiogenesis and subsequent progression of atherosclerotic lesions. Moreover, the 
effects of VEGF-A on EL were studied only in LDLR-/- and LDLR-/-ApoB100/100 mice and 
therefore, it is not known for sure whether a decrease in EL levels and an increase in HDL 
cholesterol could lead to some compensatory protective effects in these mice but not in 
apoE-deficient models. Recently, it was shown that EL has a critical role also in HDL-
induced vascular responses. HDL was shown to stimulate endothelial cell proliferation, 
tube formation and angiogenesis via sphingosine 1-phosphate signaling and these effects 
were abolished in EL-/- mice. (Tatematsu et al. 2013). Furthermore, in the current study, 
apoE-deficient mice had significantly higher plasma levels of hVEGF-A after gene transfer 
compared to LDLR-/- and LDLR-/-ApoB100/100 mice, even though the same amount of virus 
was used in all models (discussed in more detail in the following chapter 6.3). Despite this 
difference in transgene expression, LPL activity was decreased in all models. However, the 
difference in transgene expression could have been critical in the case of angiogenesis such 
that the lower amounts of hVEGF-A could have been insufficient to induce angiogenesis in 
LDLR-/- and LDLR-/-ApoB100/100 mice. 
Nevertheless, it is evident that mouse model-specific effects can explain some of the 
contradictory results seen in the literature concerning the role of VEGF-A in atherogenesis. 
It is also clear that VEGF-A is involved in the regulation of lipid metabolism. This is in line 
with the recent findings by Stathopoulou et al (2013), who reported a common genetic 
regulation between VEGF-A and cholesterol homeostatis molecules which could contribute 
to the development of atherosclerosis. However, in the current study, it remained 
somewhat unclear whether these effects in lipid metabolism could play a role in 
atherogenesis. EL and LPL have been reported to have both anti- and pro-atherogenic 
effects depending on where they are expressed (Hasham, Pillarisetti 2006). Firstly, LPL 
mRNA levels were only measured generally in different tissues and even if VEGF-A 
decreased plasma LPL activity in all models it led to changes in plasma lipids only in 
LDLR-/- models. It would be important to study the effects of VEGF-A on LPL in 
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macrophages in which the inhibition of LPL leads to atheroprotective effects (Stein, Stein 
2003). Especially, since apoE has been reported to have an anti-atherogenic role in the 
vessel wall mainly by facilitating cholesterol efflux back to the liver (Mazzone, Reardon 
1994), the LDLR-/- models could have additive anti-atherogenic effects locally in the vessel 
wall compared to apoE-deficient models: protective apoE and reduced LPL after AdVEGF-
A gene transfer. In addition, the effects of VEGF-A on EL expression were mainly studied 
in LDLR-/-ApoB100/100 mice by measuring the EL mRNA expression in different tissues. It is 
not known whether VEGF-A is able to regulate EL also in apoE-deficient models and if 
VEGF-A decreases EL activity subsequently affecting HDL cholesterol.  
It is also partly unclear at which level VEGF-A is regulating both EL and LPL. In the case 
of EL, VEGF-A inhibited SREBP-2 binding to the LIPG gene both in basal and LPDS–
induced conditions (Figure 16, I, II). However, VEGF-A was also able to increase SREBP-1 
binding. Since both SREBP-1 and -2 have been reported to be not only activators but also 
repressors of the target gene transcription, it could be that they are regulating EL 
cooperatively at least at some level leading to a net inhibitory effect (Bist, Fielding & 
Fielding 1997). In the current study, it also remained unclear how VEGF-A inhibited 
SREBP-2 binding. VEGF-A was not able to inhibit LPDS-induced activation of SREBP-2, 
however, it is possible that the mature form of SREBP-2 could undergo some post-
translational modifications by VEGF-A. In addition, EL activity was not measured and 
therefore, it is not known whether VEGF-A is regulating EL also in a post-translational 
manner similar to LPL. In the case of LPL, the effects of VEGF-A seemed to be mediated via 
both direct transcriptional regulation, and post-translationally by increasing ANGPTL4 
(Figure 17, III). However, it remained unknown what is mediating these effects and if there 
are more than one regulatory pathway activated at the same time leading to overall LPL 
inhibition. LPL has been reported to be also a target gene for SREBP activation (Schoonjans 
et al. 2000). Interestingly, when ANGPTL4 gene was analyzed using Genomatix in silico 
promoter analysis, several SREBP binding sites were predicted in the ANGPTL4 promoter 
area (Kivelä AM et al. unpublished results). In addition, 25HC, an inhibitor of SREBP 
activation, was able to inhibit ANGPTL4 expression in 3T3-L1 cells (Kivelä AM et al. 
unpublished results). Therefore, it could be possible that SREBPs regulate LPL expression 
and activity via both direct and indirect effects leading to an overall inhibition of LPL. 
Nevertheless, further investigations are needed to elucidate the specific mechanisms of 
VEGF-A regulation of lipid metabolism, in order to gain more information that would have 
strong implications for the therapeutic use of VEGF-A. 
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Figure 17. The proposed mechanism of how VEGF-A regulates LPL and the summary of the 
effects of VEGF-A on lipids and atherosclerosis based on the results presented in this thesis. The 
effects of VEGF-A on LPL are mediated via direct transcriptional regulation, and post-
translationally by increasing ANGPTL4. VEGF-A decreased LPL activity in all studied 
hyperlipidemic mouse models but increased atherosclerosis was only seen in apoE-deficient 
models. fP, fasting plasma; TG, triglycerides; TC, total cholesterol. 
 
6.3 THE EFFECTS OF LIPID METABOLISM ON ADENOVIRAL GENE 
THERAPY 
In the current study, significant differences in transgene expression were seen in different 
mouse models after systemic AdVEGF-A gene transfer although the same amount of virus 
was used in all models. In general, mice fed with a WTD had a lower transgene expression 
compared to mice on a regular chow diet. In addition, on a WTD diet, transgene expression 
was reduced in apoE-deficient models compared to C57Bl/6 mice and even further reduced 
in LDLR-/- and LDLR-/-ApoB100/100 mice. These differences most probably relate to lipid-virus 
interactions affecting the transduction efficiency of adenovirus (Figure 18). Shayakhmetov 
et al (2005) described a novel pathway for adenoviral in vivo infection instead of coxsackie-
adenovirus receptor pathway that adenovirus uses primarily in vitro. In this suggested in 
vivo pathway, adenovirus uses LRP and HSPGs for infection with the help of different 
blood factors such as coagulation factors. In this same study, it was observed that on a 
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regular chow diet adenoviral infectivity was reduced in LDLR-/- mice compared to C57Bl/6 
mice. It was suggested that not the LDL receptor-deficiency itself but the subsequent 
elevation in blood LDL levels interfere with LRP and HSPGs leading to reduced adenoviral 
infectivity. Shayakhmetov et al (2005) also excluded the involvement of apoE-containing 
lipoprotein particles in adenoviral infection since LDLR-/-ApoE-/- mice did not have further 
reduced adenoviral infectivity compared to LDLR-/- mice. (Shayakhmetov et al. 2005).  
However, when apoE is absent, lipoprotein particles are not able to bind LRP (Veniant et al. 
1998) and compete efficiently with adenovirus uptake. Therefore, it is somewhat expected 
that adenoviral infectivity is not further reduced in LDLR-/-ApoE-/- mice. In the study by 
Shayakhmetov et al (2005), mice were also only fed with a regular chow diet. In the current 
study, when mice were challenged with a WTD, the role of apoE-containing lipoproteins 
became critical. LDLR-/- mice had significantly lower transgene expression after AdVEGF-A 
gene transfer compared to LDLR-/-ApoE-/- mice. This is not surprising since LDL receptor is 
mediating the uptake of apoE-containing particles together with LRP (Veniant et al. 1998). 
When LDL receptor is absent, LRP becomes the main receptor uptaking apoE-containing 
particles in the liver and most probably leads to more efficient competition with 
adenovirus. In addition, apoE-containing particles can also bind to HSPGs and compete 
with the binding of adenovirus.  Although it seems likely that LRP truly is mediating the 
adenovirus uptake into the hepatocytes in vivo, the role of LDL receptor itself in this uptake 
can not be totally ruled out.  
 
 
 
Figure 18. The proposed mechanism how the lipoproteins are affecting adenoviral infection in 
vivo. Adenovirus (Ad) binds to LRP and HSPGs in vivo and infects liver cells leading to an 
increased transgene expression. In LDL receptor (LDLR)-deficiency, the increased lipid levels 
are competing with the virus uptake by binding to LRP and HSPGs via apoE-interaction leading 
to a decreased transgene expression. In apoE-deficiency, lipid particles are unable to bind LRP 
and HSPGs leading to an inefficient blocking of the virus uptake and transgene expression. 
 
These differences in transgene expression became very important when the effects of 
AdVEGF-A were studied in different hyperlipidemic mouse models. The higher expression 
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of VEGF-A in apoE-deficient models could have been the reason for the increased 
atherosclerosis seen in those models and more importantly, the high expression of VEGF-A 
was even lethal in some of the models. 
Physiological LDL cholesterol level in humans is 1.5 mmol/l (Goldstein, Brown 1977). It 
is the level after which LDL receptors saturate and become less efficient in the clearance of 
lipoprotein particles. It is also the level that is possible to reach with an effective statin 
treatment leading to regression of atherosclerotic plaques (Nissen et al. 2006), whereas LDL 
cholesterol levels above 2.0 mmol/l enable plaque growth to continue (Nissen et al. 2004). 
The mean LDL cholesterol level of different mammalian species that do not naturally 
develop atherosclerosis is as low as 0.8 mmol/l, which is similar to the level that human 
newborn infants have at a time before dietary or other environmental stresses have 
elevated it (Goldstein, Brown 1977). The so called normal LDL cholesterol level in humans 
is already twice as high as the physiological level. With effective statin treatments, the new 
goals have been set to reach LDL cholesterol levels close to the physiological level since no 
adverse effects on safety with lower LDL cholesterol levels have been observed (Wiviott et 
al. 2005). It is likely that the high LDL cholesterol levels of humans today are a result of 
evolutionary changes and diet. However, it has been reported that lipoproteins are also 
able to bind and neutralize a wide variety of viruses and therefore, lipoproteins participate 
in the innate immunity and are the first line host defense against invading viruses 
(Khovidhunkit et al. 2004). It is intriguing to speculate that higher LDL cholesterol levels 
could have become beneficial against viral infections during evolution and therefore, 
targeting too low cholesterol levels could lead to less efficient defence against viral 
infections in man. 
  
53 
 
 
7  Conclusions 
The following conclusions can be drawn based on the results of this study: 
 
 
I  EL is transcriptionally regulated by the classical NF-B pathway in human 
endothelial cells after inflammatory stimuli. In addition, SFN downregulates 
EL expression by interfering with the NF-B pathway. 
 
II SREBPs are novel regulators of EL expression in human endothelial cells. 
Moreover, VEGF-A inhibits EL expression both in vitro and in vivo and 
increases HDL cholesterol levels in a mouse model of atherosclerosis. EL 
regulation by VEGF-A is at least partly SREBP-dependent.  
 
III VEGF-A induces alterations in lipid profiles and reduces LPL activity in all 
studied hyperlipidemic mouse models. However, VEGF-A increases 
atherosclerosis only in the ApoE-/- background indicating some mouse model-
specific effects. 
 
 
Taken together, this study provides new information about the transcriptional regulation 
of EL. The classical NF-B pathway is regulating EL expression after inflammatory stimuli. 
However, EL expression is also modulated by SREBPs providing one possible mechanism 
for cells to respond to changes in cholesterol levels. Since EL is a major physiological 
regulator of HDL metabolism, therapies aiming at reducing its expression are of great 
interest. SFN decreases EL expression via inhibition of NF-B suggesting that SFN could 
have vasculoprotective effects not only via its anti-inflammatory properties but also via 
beneficial effects on lipid metabolism. Furthermore, VEGF-A clearly plays a role in lipid 
metabolism via regulation of EL and LPL leading to changes in plasma lipids. In addition, 
VEGF-A increases atherosclerosis only in apoE-deficient models indicating some mouse 
model-specific effects likely explaining previous contradictory results seen in the literature. 
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The protective role of high density 
lipoprotein (HDL) against coronary 
heart disease and atherosclerosis 
is well established. Endothelial 
lipase (EL) is a major regulator of 
HDL metabolism and therefore an 
intriguing therapeutic target for 
increasing HDL cholesterol. In this 
thesis, potential factors modulating 
EL expression via transcriptional 
regulation were investigated. Also, 
the effects of VEGF-A in lipid 
metabolism were assessed since its 
role in atherosclerosis is still under 
debate. 
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